CURRICULUM VITAE
DATE:
May 19, 2014
NAME:
Marc Klapholz, MD
PRESENT TITLE:
Professor & Chair, Department of Medicine
Chief of Service
Director, Division of Cardiology
HOME ADDRESS:
30 West 60th Street, Apt. 9A, New York, NY 10023
OFFICE ADDRESS:
Rutgers - New Jersey Medical School
Medical Science Building, I Level, Room 536
185 So. Orange Avenue, Newark, NJ 07103
TELEPHONE NUMBER/E-MAIL ADDRESS:
CITIZENSHIP:
(973) 972-4731 (Administrative)
(973) 972-2573 (Private Practice)
(917) 865 - 5393 (Mobile)
klapholz@njms.rutgers.edu
USA
EDUCATION:
A. Undergraduate Graduate and Professional
Yeshiva University College
New York, NY
B.A. - Summa Cum Laude
B. Graduate and Professional
Albert Einstein College of Medicine
Bronx, NY
M.D.
POSTGRADUATE TRAINING:
A. Internship and Residencies
St. Luke’s Hospital, New York, NY
Internship - Internal Medicine
Albert Einstein College of Medicine & the Bronx Municipal
Hospital Center, Bronx, NY
Residency - Internal Medicine
Fellowship - Cardiology
1981
1986
1986 - 1987
1987 - 1989
1990 - 1992
Albert Einstein College of Medicine, Bronx NY
Interventional Cardiology. Training/Certification in Angioplasty, Stent
Placement, Rotational and Directional Atherectomy and Balloon
Valvuloplasty
1994 - 1995
B. Research Fellowships
Albert Einstein College of Medicine, Bronx, NY
NIH National Research Service Award
Clinical Research Fellow - Heart Failure Group
C. Postdoctoral Appointments
None
Page 1 of 40
1989 - 1990
MILITARY:
None
ACADEMIC APPOINTMENTS:
Rutgers - New Jersey Medical School
Department of Medicine
Chair, Department of Medicine
Professor of Medicine
Associate Professor of Medicine
Assistant Professor of Clinical Medicine
3/2012- Present
7/2008 - Present
1/2005 - 7/2008
5/1996 - 3/2000
New York Medical College
Department of Medicine
Associate Professor of Medicine
1/2001 - 12/2004
Albert Einstein College of Medicine
Department of Medicine
Visiting Instructor in Medicine
Instructor - Cardiovascular Section, School of Perfusion Technology
7/1994 - 6/1995
7/1990 - 6/1991
Columbia College of Physicians and Surgeons
Department of Medicine
Assistant Professor of Clinical Medicine
7/1993 - 6/1995
HOSPITAL APPOINTMENTS:
University Hospital
Department of Medicine
Chief of Service, Department of Medicine
Director, Division of Cardiology
Fellowship Program Director, Division of Cardiology
Interventional Fellowship Program Director, Division of Cardiology
Director, Heart Failure Program
Director, Cardiac Catheterization Laboratory
Director, Cardiac Catheterization Laboratory
Associate Director, Cardiac Catheterization Laboratory
Attending Physician
Associate Attending
Director, Cardiac Care Unit, Telemetry Unit & Heart Failure Program
3/2012 - Present
8/2004 - Present
8/2004 - 4/2012
1/2013 - Present
8/2004 - Present
9/2004 - 7/2006
1/1998 - 11/1999
11/1995 - 12/1997
8/2004 - Present
7/1995 - 11/1999
11/1995 - 11/1999
Saint Vincent’s Catholic Medical Center
Department of Medicine
Chief, Heart Failure Prevention and Treatment Program
Chief, Cardiovascular Research
Associate Attending
11/1999 - 8/2004
4/2003 - 8/2004
11/1999 - 7/2004
St. Luke's/Roosevelt Hospital Center
Department of Medicine
Assistant Medical Attending
Director, Heart Failure Program
Associate Director, Cardiac Care Unit
Associate Director, Echocardiography Laboratory
7/1992 - 6/1994
7/1992 - 6/1994
7/1992 - 6/1993
7/1993 - 6/1994
Bronx Municipal Hospital Center
Department of Medicine
Assistant Attending Physician
7/1990 - 6/1995
Page 2 of 40
Hospital of the Albert Einstein College of Medicine
Department of Medicine
Attending Physician, Evaluation Unit
Junior Medical Attending
7/1989 - 6/1992
7/1989 - 6/1990
OTHER EMPLOYMENT OR MAJOR VISITNG APPOINTMENTS:
Visiting Professor at the Heart Center of Konyang University Hospital. Daejeon City, South Korea.
April 17-23, 2010.
Visiting Professor at Yokohama University at the invitation of the Japanese Government. Tokyo, Japan.
January 10-11, 2008.
PRIVATE PRACTICE Doctors Office Center
90 Bergen Street, Suite 3500
Newark, NJ 07103
8/2004 - Present
Heart Failure Prevention and Treatment Program
Saint Vincent’s Catholic Medical Center
170 West 12th Street - Spellman 9th Floor
New York, NY 10011
LICENSURE:
11/1999 - 7/2004
New York State Medical License 174481-1
Exp. June 30, 2015
New Jersey State Medical License 25MA06249400 Exp. June 30, 2015
DRUG LICENSURE:
CDS:
New Jersey State
D06683601
Exp. October 31, 2014
DEA:
New Jersey State
New York State
BK9035519
BK4589505
Exp. December 31, 2016
Exp. December 31, 2016
CERTIFICATION:
Diplomate of the National Boards of Medical Examiners / No. 323907/ July 1, 1987
Diplomate Certified: Internal Medicine / No. 124653 / September 13, 1989 - indefinitely
Diplomate Certified: Cardiovascular Disease / No. 124653 / November 6, 1991.
Recertified: 2002 - 2012; 2012 - 2022
Diplomate Certified: Adult Comprehensive Echocardiography / June 21, 1997.
Recertified: 2008 - 2017
Diplomate Certified: Interventional Cardiology / No. 124653 / November 3, 1999.
Recertified: 2009 - 2019
Diplomate Certified: Advance Heart Failure/Transplant Cardiology / No. 124653 / November 8, 2010 December 31, 2020
MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL
SOCIETIES:
American Heart Association
Member, STEMI Workgroup - NJ State
2008 - Present
American College of Cardiology
Member, National Committee, Learning Portfolio Workshop
2007 - 2011
Page 3 of 40
Heart Failure Society of America
Member, Guidelines Committee
2006 - 2010
American College of Cardiology, New Jersey State Chapter
Governing Councilor
2005 - Present
Pulmonary Hypertension Clinical Research Association
Member
2004 - Present
New York Cardiologic Society Program Committee
Member
2003 - 2007
American College of Cardiology, New York State Chapter
Governing Councilor, New York City Region
2003 - 2005
American Heart Association (Heritage Affiliate)
Member, Research Grant Review
2000, 2002 - 2004
Heart Failure Society of America
Member
1998 - Present
Society for Coronary Angiography & Interventions
Fellow
1997 - Present
American Heart Association
Member
1993 - Present
American Medical Association
Member
1990 - Present
HONORS AND AWARDS:
Best Doctors in America
2013
Ranked #1 by University Hospital Consortium in Heart Failure Mortality
University of Medicine & Dentistry of New Jersey - University Hospital
(Director, Marc Klapholz, MD)
2012
Ranked #1 by University Hospital Consortium in Heart Failure Core Measures
University of Medicine & Dentistry of New Jersey - University Hospital
(Director, Marc Klapholz, MD)
2011, 2012
Advanced Certification in Heart Failure: Joint Commission
Recertified:
University of Medicine & Dentistry of New Jersey - University Hospital
(Program Director, Marc Klapholz, MD)
2010
2013
‘Best Doctors in New York’
New York Magazine
1999 - 2007, 2012
Cardiology Fellowship Program 5 year accreditation with commendations
University of Medicine & Dentistry of New Jersey - University Hospital
(Program Director, Marc Klapholz, MD)
2010
‘Top Doctors 5th Anniversary in the New York Metro Area’
New York Magazine
2010
Page 4 of 40
‘Faculty of the Year’, Clinical Science Award
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2010
‘Top Doctors in the State’
New Jersey Monthly
2007, 2010
Faculty Research Award, Department of Medicine
Saint Vincent’s Catholic Medical Center
NIH National Research Service Award, Department of Medicine
Albert Einstein College of Medicine
Leo M. Davidoff Award for Excellence in Teaching Medical Students
Albert Einstein College of Medicine
2001
1989
1988
Summa Cum Laude
Yeshiva University
1981
BOARDS OF DIRECTORS/TRUSTEES POSITIONS:
Heart Failure Society of New Jersey
Founding Member: Heart Failure Consortium of New Jersey
Executive Council - Board of Trustees
2007 - Present
SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:
American Heart Association
Member, National Research Grant Review Committee
2002 - 2003
SERVICE ON MAJOR COMMITTEES:
A. International
Chair, Data Safety Monitoring Board: Safety and Efficacy of Enoxaparin in PCI Patients, an International
Randomized Evaluation. STEEPLE Trial.
Sponsor: Novartis.
2004
Chair, Endpoints Committee: Multicenter Randomized Placebo Controlled Trial of Darbopoetin in the
Treatment of Heart Failure, STAMINA-Heft.
Sponsor: Amgen, Inc.
2002
Member, Steering Committee: The Studies of Oral Enoximone Therapy in Advanced Heart Failure.
Protocol My-021 (North and South America) and Protocol My-026 (Eastern and Western Europe).
Sponsor: Myogen, Inc.
2001
Member, Steering Committee: International Randomized Placebo Controlled Trial to Evaluate the Effect of
Enrasentan for the Treatment of Mild Heart Failure.
Sponsor: Glaxo-Smith Kline.
2000
Member, Endpoints Committee: Randomized Double Blind, Positive and Placebo Controlled Multicenter
Dose Ranging Study to Assess the Efficacy, Tolerability and Safety of SKB-2317242 in Patients with Stable
NYHA II-III Congestive Heart Failure.
Sponsor: SmithKline.
1999
Page 5 of 40
B. National
Member, Laptop HF Steering Committee
Sponsor: St. Jude Medical, Inc.
2009 - Present
Chair, Clinical Events Committee: Evaluation of HeartNet Ventricular Support
System in Heart Failure Patients treated with Cardiac Resynchronization Therapy.
2011
Member, Exeleras Protocol Writing Committee. Sponsor: Orqis Medical Corporation.
2007 - 2008
Chair, Endpoint Committee: Hemodynamically Guided Home Self-Therapy in Severe
Heart Failure Patients (HOMEOSTASIS II). Sponsor: Savacor Therapeutics.
2006 - 2011
Chair, Endpoint Committee: CASPER Trial: Sponsor: GlaxoSmith Kline (GSK).
2005 - 2007
Chair, Endpoint Committee: Chronicle ICD Study. Sponsor: Medtronic, Inc.
2005 - 2007
Chair, Endpoint Committee: Paracor Heart Failure Trial (Restraining Mesh Device).
Sponsor: Paracor, Inc.
2005 - 2011
Member, Endpoint Committee: PRECEDE HF Study. Sponsor: Medtronic, Inc.
2005 - 2000
Chair, Endpoint Committee: Chronicle Offers Management to Patients with Advanced
Signs & Symptoms of Heart Failure - COMPASS-HF. Sponsor: Medtronic, Inc.
2004 - 2007
Member, Endpoints Committee: Multicenter, Randomized, Double Blind Controlled Trial
of OPC-8292 versus Dobutamine on the Hemodynamic Effects and Safety in Patients
with Decompensated Heart Failure. Sponsor: OTSUKA Pharmaceuticals, Inc.
1998 - 2002
C. Medical School/University
Member, UMDNJ & UH Separation Steering Committee
University of Medicine & Dentistry of New Jersey - University Hospital
- Team Leader, Ambulatory Care Subgroup
- Team Leader, Clinical Operations Subgroup
2012 - Present
2012 - Present
2012 - Present
Chair, New Jersey Medical School Neurology & Neuroscience Chair Search Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
11/2012 - Present
Member, RU-UMDNJ Clinical Integration: Operations Sub Team Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
9/2012 - Present
Member, New Jersey Medical School Strategic Planning Steering Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1/2012 - Present
Member, Bio-Trials & Parexel Collaboration Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
12/2011 - Present
Member, Multi-Specialty (Integrated) Faculty Practice Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
11/2011 - Present
Chair, New Jersey Medical School Dean Search Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
4/2010 - 3/2011
Member, Dean’s Department of Medicine Task Force Meeting
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2010 - Present
Page 6 of 40
Member, Strategic and Finance Committee (Track Team 3)
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2009 - 2011
Member, M.D. with Research Thesis Program
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2010 - 2011
Member, Department of Emergency Medicine Recruitment Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2010 - Present
Chair & Member, Faculty Practice Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2005- Present
Member, Institutional Planning & Development Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2009 - 2011
Member, Managed Care Reimbursement Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2009 - 2012
Member, Interview & Recruitment Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2008 - 2010
Member, Joint Committee for Compliance in Clinical Research
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2008 - 2010
Member, Faculty Council
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2006 - Present
Member, Faculty Organization
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2006 - Present
Dean’s Administrative Oversight Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1998 - 1999
Institutional Review Board for Research Activities
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1998 - 1999
Senate, Albert Einstein College of Medicine
1984 - 1985
D. Hospital
Chair & Member, Endovascular Working Group
University of Medicine & Dentistry of New Jersey - University Hospital
2008 - 2012
Member, Governing Council & Medical Executive Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2008 - 2012
Member, Combined Critical Care Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2007 - 2010
Medical Chair, Safe Team Approach to Medication Practices (STAMP)
University of Medicine & Dentistry of New Jersey - University Hospital
2007 - 2008
Chair, Cardiology Core Measures / 8th Scope of Work Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2005 - Present
Page 7 of 40
Divisional Representative to Hospital Quality Assurance Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2005 - Present
Medical Chair, Medication Reconciliation Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2005 - 2007
Chair, Cardiovascular Services Committee
University of Medicine & Dentistry of New Jersey - University Hospital
2004 - Present
Member, In-Patient Physician Work Group
University of Medicine & Dentistry of New Jersey - University Hospital
2009 - 2010
Chair, Pharmacy and Therapeutic Committee
Saint Vincent’s Catholic Medical Center, Manhattan Division
2004
Member, Research Committee
Saint Vincent’s Catholic Medical Center, Manhattan Division
2003 - 2004
Member, Catheterization Laboratory Committee - Construction and Technology Acquisition
Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Member, Peripheral Vascular Intervention Credentialing Committee
Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Member, JCAHO Quality Improvement Committee
Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Member, Hospital Quality Review Committee
Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Member, Operative and Invasive Procedure Review Committee
University of Medicine & Dentistry of New Jersey - University Hospital
1998 - 1999
Medical Chair, Cardiac Catheterization Construction Committee
University of Medicine & Dentistry of New Jersey - University Hospital
1996 - 1997
Member, Medical Board Quality Assurance Cardiac Catheterization Laboratory
Weiler Hospital, Albert Einstein College of Medicine
1994 - 1995
Member, Medical Board Quality Assurance Committee for Critical Care
St. Luke’s / Roosevelt Hospital Center
1992 - 1993
E. Department
Chair, Department of Medicine Faculty Practice Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2006 - Present
Member, CRG Committee, Department of Medicine
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2005 - 2009
Member, Cardiology Process & Improvement Committee, Department of Medicine
Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Member, Expanded Executive Committee, Comprehensive Cardiovascular Center,
Department of Medicine Saint Vincent’s Catholic Medical Center, Manhattan Division
2000 - 2004
Page 8 of 40
Chair, Quality Assurance Cardiac Catheterization Laboratory, Department of Medicine
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1996 - 1997
Member, Department of Medicine Quality Assurance Committee
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1995 - 1999
Member, Critical Care, Quality Assurance Committee, Department of Medicine
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
1995 – 1997
F.
Editorial Boards
Section Editor, Heart Failure & Cardiomyopathy - Cardiology in Review
2007 - Present
Editorial Board, Heart Disease: Editor: William Frishman
2002 - 2006
Literature Alert Editor, Current Cardiology Reports: Editor: Valentin Fuster
1999 - 2000
G. AdHoc Reviewer
Circulation
2008 - Present
Journal of the American College of Cardiology
2008 - Present
American Journal of Cardiology
2008 - Present
American College of Cardiology-Scientific Sessions
Abstract Reviewer
2007
Journal of Cardiac Failure
2004
SERVICE ON GRADUATE SCHOOL COMMITTEES: None
SERVICE ON HOSPITAL COMMITTEES:
‘See Service on Major Committees - D’
SERVICE TO THE COMMUNITY: Annual Cardiovascular Community Screenings
SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE:
SPONSORSHIP OF POSTDOCTORAL FELLOWS:
TEACHING RESPONSIBILITIES:
A. Lectures or Course Directorships
2006 - Present
None
None
(CME Accredited)
Hot Topics Update in Internal Medicine: “Cardiology: Pulmonary Hypertension for the Internist”. Rutgers
New Jersey Medical School, Department of Medicine and Center for Continuing & Outreach Education at
Rutgers Biomedical & Health Sciences. September 27, 2014.
Grand Rounds: “State of the Department of Medicine”. Rutgers New Jersey Medical School, Newark, NJ.
September 16, 2014.
Internal Medicine CME Lecture: “Pulmonary Arterial Hypertension”. St. Joseph’s Regional Medical Center,
Paterson, NJ. May 14, 2014.
Medical Grand Rounds: “New-Pharmacologic and Non-Pharmacologic Approaches in the Treatment of Heart
Failure”. Hackensack University Medical Center, Hackensack, NJ. April 22, 2014.
Page 9 of 40
Saturday Morning Conference: “Heart Failure”. Delaware County Memorial Hospital. Drexel Hill, PA.
January 25, 2014
Grand Rounds: “Heart Failure – Current Trends and Practices”. Jersey City Medical Center. Jersey City, NJ.
December 11, 2013.
1st Annual Update on Liver Diseases: Hepato and Portopulmonary Hypertension Syndrome: Is it the Heart, the
Lungs, or the Liver?” Rutgers New Jersey Medical School, Newark, NJ. November 23, 2013.
American Association of Indian Physicians Cardiology Symposium: “Heart Failure - Current and Future
Trends and Practices”. Newark, NJ. June 22, 2013.
Plenary Speaker: “Diagnosing and Managing Heart Failure in 2013”. New Jersey Chapter - ACP Scientific
Meeting, Iselin, NJ. March 8, 2013.
Medical Grand Rounds: “Heart Failure - Current Trends and Practices”. Newark Beth Israel Medical Center,
Newark, NJ. January 31, 2013.
Grand Rounds: “Congestive Heart Failure”. Palisades Medical Center, North Bergen, NJ. January 3, 2013.
Grand Rounds: “Heart Failure Current Trends and Practices”. UMDNJ - New Jersey Medical School,
Newark, NJ. November 13, 2012.
Grand Rounds: “New Therapies in the Treatment of Heart Failure”. Lankenau Medical Center (Main Line
Health), Wynnewood, PA. November 7, 2012.
Grand Rounds: “Heart Failure II”. Hoboken University Medical Center, Hoboken, NJ. October 17, 2012.
Internal Medicine CME Lecture: “Heart Failure”. St. Joseph’s Regional Medical Center, Paterson, NJ.
May 23, 2012.
Grand Rounds: “Heart Failure”. Hoboken University Medical Center, Hoboken, NJ. May 2, 2012.
Grand Rounds: “Congestive Heart Failure”. Richmond University Medical Center, Staten Island, NY.
December 6, 2011.
5th Annual Critical Care Symposium: “NSTE-ACS - Non ST Elevation Acute Coronary Syndrome. Centra
State Medical Center, Freehold, NJ. December 3, 2011.
Grand Rounds: “Pulmonary Hypertension”. East Orange General Hospital, East Orange, NJ.
September 27, 2011.
Grand Rounds: “Pulmonary Hypertension”. Bayonne Medical Center, Bayonne, NJ.
May 6, 2011.
Grand Rounds: “Treatment of Acute and Chronic Heart Failure”. The Mount Vernon Hospital, Mount Vernon,
NY. February 16, 2011.
Fourth Annual New York Cardiac Lecture: “Acute Decompensated Heart Failure”. Stony Brook Medical
Center, Stony Brook, NY. December 15, 2010.
Medicine Grand Rounds: “Acute Heart Failure”. UMDNJ - New Jersey Medical School, Newark, NJ.
December 14, 2010.
Grand Rounds: “Chronic Heart Failure Update 2010”, Bayonne Medical Center, Bayonne, NJ. May 7, 2010.
Page 10 of 40
Simulations & Wireless Technologies Symposium: “Wireless Technology Improves Outcomes & Eliminates
Gender Bias in Acute Myocardial Infarction”, Robert Wood Johnson, New Brunswick, NJ. April 13, 2010.
Medical Ground Rounds: “Changing Paradigms and Therapeutic Opportunities in the Diagnosis and Treatment
of Heart Failure”, Hackensack University Medical Center, Hackensack, NJ. March 9, 2010.
Emergency Medicine Grand Rounds: “Changing Paradigms and Therapeutic Opportunities in the Diagnosis
and Treatment of Heart Failure”, UMDNJ - University Hospital, Newark, NJ. December 30, 2009.
Medical Grand Rounds: “Advances in the Diagnosis and Treatment of Heart Failure”, University Medical
Center at Princeton, Princeton, NJ. December 8, 2009.
Medical Grand Rounds: “Congestive Heart Failure”, Mountainside Hospital, Montclair, NJ.
November 5, 2009.
Medical Grand Rounds: “Pulmonary Hypertension”, Trinitas Hospital, Elizabeth, NJ. October 22, 2009.
“Changing Paradigms and Therapeutic Opportunities in the Diagnosis and Treatment of Heart Failure”, United
Medical Center, Washington, DC. July 8, 2009.
Medicine Grand Rounds: “Heart Failure Update 2009” UMDNJ - New Jersey Medical School, Newark, NJ.
June 9, 2009.
NJHI Expecting Success: Excellence in Cardiac Care: “Sharing Successes and Sustainability”, Princeton, NJ.
May 12, 2009.
Annual Internal Medicine Conference: “Update on Heart Failure”, Richmond University Medical Center,
Staten Island, NY. May 11, 2009.
Heart Failure Consortium of New Jersey: “Heart Failure Update 2009”, Ridgewood, NJ. April 28, 2009.
Cardiology Grand Rounds: “Heart Failure Update 2009”, UMDNJ - Robert Wood Johnson, New Brunswick,
NJ. April 13, 2009.
Grand Rounds: ‘Heart Failure’, Saint Joseph Medical Center, Paterson, NJ. December 31, 2008.
‘NJ Statewide Prehospital STEMI Triage Guideline Discussion Panel’, New Jersey State Conference on EMS,
Atlantic City, NJ. October 2, 2008.
“Management of Myocardial Infarction Patients”. New Brunswick, NJ. September 19, 2008.
Heart Failure Society of New Jersey: “Heart Failure Update”, Atlantic City, NJ. September 4, 2008.
‘Pooled safety analysis of darbeopoetin alfa in the treatment of symptomatic heart failure’. European Society
of Cardiology, Munich, Germany. September 2, 2008.
American Heart Association: “Heart Failure Summit: Failure is Not An Option”. Parsippany, NJ. June 2,
2008.
Medicine Grand Rounds: “Heart Failure 2008” UMDNJ - New Jersey Medical School, Newark, NJ.
March 18, 2008.
Emergency Medicine Grand Rounds: ‘Heart Failure’ UMDNJ - University Hospital, Newark, NJ. November
21, 2007.
‘Cardiac Catheterization Laboratory & Congestive Heart Failure: No Longer Just a Right Heart Cath!’
Transcatheter Cardiovascular Therapeutics Symposium, Washington, DC. October 21, 2007.
Page 11 of 40
Statewide Conference Call / WebEx - Healthcare Quality Strategies, Inc. (HQSI).
‘Shortening Door to Balloon Time - A Novel Approach Using a Fully Automated Wireless Network’.
July 25, 2007.
Round Table Program ‘Optimal Treatment for the Post MI LVD Patient: Focus on B-Blockers’, Philadelphia,
PA. April 26, 2007.
Round Table Program ‘Current Strategies in the Diagnosis and Treatment for Patients with Pulmonary Arterial
Hypertension’, Edison, NJ. April 11, 2007.
Vascular Grand Rounds: ‘New Devices for Congestive Heart Failure’, UMDNJ - University Hospital, Newark,
NJ. January 9, 2007.
Medical Staff Grand Rounds: Community Medical Center: ‘New Approaches in Managing Diastolic Heart
Failure’, Toms River, NJ. October 21, 2006.
Cancer and Cardiovascular Disease: ‘Increasing the Success of Chemotherapy by Reducing CVD as a Barrier
and Long-Term Risk’. Houston, TX. October 13-14, 2006.
The Society of Hospital Medicine Annual Meeting: ‘A Head Start on Heart Failure: The Hospitalist’s Role in
Optimizing Long-Term Patient Outcomes’. Washington, DC. May 5, 2006.
Cardiology Grand Rounds: ‘Heart Failure: Beyond Neurohormones’, The Stamford Hospital, Stamford, CT.
December 16, 2005.
Department of Medicine Grand Rounds: ‘Heart Failure 2006’, Saint Vincent’s Catholic Medical Centers, Staten
Island, NY. December 6, 2005.
Department of Medicine Grand Rounds: ‘Update on Congestive Heart Failure 2005’, Saint Mary Hospital,
Hoboken, NJ. October 5, 2005.
Department of Medicine Grand Rounds: ‘New Insights in the Treatment of Post-MI LVD and HF’, Saint
Michael’s Medical Center, Newark, NJ. August 17, 2005.
North Jersey Medical Society: ‘Optimizing Vascular Protection: The Role of Angiotensin II Blockade’, West
Orange, NJ. June 22, 2005.
Department of Medicine Grand Rounds: Fluid Matrix: ‘Managing Neurohormones and Electrolytes’, Casa
Promesa, Bronx, NY. May 26, 2005.
Cardiology Grand Rounds: ‘Heart Failure Update 2005’, Saint Vincent’s Hospital, New York, NY.
May 13, 2005.
Cardiology Grand Rounds: Fluid Matrix: ‘Managing Neurohormones and Electrolytes’, Jersey City
Medical Center, Jersey City, NJ. April 20, 2005.
Cardiology Grand Rounds: Fluid Matrix: ‘Managing Neurohormones and Electrolytes’, LIJ - Browns Mill,
NJ. March 31, 2005.
Cardiology Grand Rounds: ‘Heart Failure 2005 ½’; East Orange VA, East Orange, NJ. March 23, 2005.
Department of Medicine Grand Rounds: ‘Heart Failure, Gemini & Diastolic Heart Failure’, White Plains
Hospital, White Plains, NY. February 1, 2005.
Cardiology Grand Rounds: ‘Diastolic Dysfunction Heart Failure Mechanisms and Demographics’,
St. Luke’s/Roosevelt Hospital, New York, NY. March 24, 2004.
Page 12 of 40
Department of Medicine Grand Rounds: ‘Evolving Therapeutic Strategies in the Management Left Ventricular
Dysfunction’, Queens General Hospital, Jamaica, NY. March 10, 2004.
Department of Community Medicine Grand Rounds: ‘Management of Acutely Decompensated Heart Failure
in the Normal Ejection Fraction Patient’, Saint Vincent’s Catholic Medical Center, New York, NY.
February 25, 2004.
Department of Medicine Grand Rounds: ‘Heart Failure: What Have We Learned in 2003’, Albert Einstein
Medical Center, Philadelphia, PA. January 7, 2004.
Department of General Medicine Grand Rounds: ‘Heart Failure: Where are We and What’s Next’, Saint
Vincent’s Catholic Medical Center, New York, NY. November 21, 2003.
Primary Care Medicine Grand Rounds: ‘Changing Paradigms in Heart Failure’, Saint Vincent’s Catholic
Medical Center, New York, NY. November 4, 2003.
7th Annual Scientific Meeting of the Japanese Heart Failure Society: ‘Clinical Characteristics, Hospital Course
and Long-Term Outcome of Patients Hospitalized for Heart Failure with a Normal Left Ventricular Ejection
Fraction’, Osaka, Japan. October 24, 2003.
Department of Geriatrics Grand Rounds: ‘Heart Failure: Treatment with Beta-Blockade’,
St. Luke’s/Roosevelt Medical Center, New York, NY. September 5, 2003.
World Medical Conference: ‘Managing LV Dysfunction: The Electronic Revolution’, Daytona Beach, FL.
July 11, 2003.
World Medical Conference: ‘New and Emerging Therapies in Post-MI Patients’, New Orleans, LA.
June 28, 2003.
Department of Medicine Grand Rounds: ‘Progression and Treatment of Heart Failure’, Mary Immaculate
Hospital, Jamaica, NY. May 16, 2003.
Medical Conferences: ‘The Diabetic Hypertensive Patient with Stable Angina and Acute MI’, Nashville, TN.
May 10, 2003.
Department of Medicine Grand Rounds: ‘Update on the Treatment of Heart Failure’, Cornell Medical Center,
New York, NY. March 17, 2003.
Department of Community Medicine Academic Training Program: ‘Cardiomyopathy and Diastolic
Dysfunction’, Saint Vincent Catholic Medical Center, New York, NY. January 28, 2003.
Department of Medicine Grand Rounds: ‘The Use of Beta-Blockers in Heart Failure’, Pascack Valley
Hospital, Westwood, NJ. November 22, 2002.
Department of Medicine Grand Rounds: ‘Update on the Treatment of Heart Failure’, Saint Vincent Catholic
Medical Centers, New York, NY. October 4, 2002.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, Queens Hospital, Jamaica,
NY. September 18, 2002.
Department of Medicine Grand Rounds: ‘Update on the Treatment on Heart Failure’, Central Suffolk Hospital,
Riverhead, NY. June 11, 2002.
Department of Medicine - The Spring 2002 Update in Internal Medicine: ‘New Approaches to Treatment of
Acute CHF: The Role of BNP’, Saint Vincent’s Catholic Medical Centers, Staten Island, NY. May 20, 2002.
Page 13 of 40
28th Annual Cardiac Scientific Teaching Day: ‘Update in the Treatment of Heart Failure’, Kutsher's Country
Club, Monticello, NY. May 8, 2002.
Department of Community Medicine: ‘Congestive Heart Failure - Update/Review’, Saint Vincent’s Catholic
Medical Centers, New York, NY. April 9, 2002.
Department of Medicine Grand Rounds: ‘Emerging Epidemiology and New Therapies in Heart Failure’, Our
Lady of Mercy Hospital, Bronx, NY. February 20, 2002.
Emergency Department ‘Natriuretic Peptide: Diagnostic Aid and Therapeutic Tool’, Saint Vincent’s Catholic
Medical Center, New York, NY. February 15, 2002.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, SUNY Downstate, Brooklyn,
NY. February 13, 2002.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, St. Claire’s Hospital, New
York, NY. February 8, 2002.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, Cabrini Medical Center, New
York, NY. February 4, 2002.
Department of Medicine Grand Rounds ‘Emerging Therapies in Heart Failure’, Lutheran Medical Center,
Brooklyn, New York, NY. January 3, 2002.
Cardiology Grand Rounds: ‘Emerging Therapies in Heart Failure’, Brooklyn VA Medical Center, Brooklyn,
NY. December 13, 2001.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, North General Hospital, New
York, NY. December 4, 2001.
Department of Medicine Grand Rounds: ‘Management of Acutely Decompensated Heart Failure: The Role of
Natriuretic Peptide’, Woodhull Medical Center, Brooklyn, NY. November 26, 2001.
Saint Vincent’s Catholic Medical Centers, NY: Symposium; ‘New Concepts in Heart Failure’ Program Chair;
CME Accreditation - New York Medical College, New York, NY. October 30, 2001.
Department of Medicine Grand Rounds: ‘Emerging Concepts in Cardiac Failure’, Albert Einstein New York
Medical College, Philadelphia, PA. October 17, 2001.
Department of Medicine Grand Rounds: ‘Changing Epidemiology and Emerging Therapies in Heart Failure’,
Saint Vincent’s Catholic Medical Center, New York, NY. October 12, 2001.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, Community Hospital,
Brooklyn, New York. September 21, 2001.
Heart Failure Society of America, Meetings 2001: Satellite Symposium: ‘The Heart and Kidney as Targets for
the Renin-Angiotensin System; Understanding Diastolic Dysfunction: From Epidemiology to
Pathophysiology’. CME Accreditation - University of Minnesota. September 2001.
Department of Medicine/Geriatrics: ‘Clinical Characteristics and Co-Morbid Conditions in Patients
Hospitalized for Heart Failure with Normal Systolic Function’, Saint Vincent’s Catholic Medical Center, New
York, NY. June 29, 2001.
Department of Medicine Grand Rounds: ‘Emerging Therapies in Heart Failure’, Brookdale Medical Center,
Brooklyn, New York, NY. June 14, 2001.
Page 14 of 40
Department of Medicine Grand Rounds: ‘Emerging Pharmacological Therapies in Heart Failure’, Saint
Vincent’s Catholic Medical Center, Staten Island, NY.
May 29, 2001.
Department of Medicine Section of Rehabilitation Grand Rounds: ‘Interventions and Rehabilitation in Heart
Failure and Effect on Cardiopulmonary Testing’, Saint Vincent’s Catholic Medical Centers, New York, NY.
March 22, 2001.
Department of Medicine Grand Rounds: ‘Heart Failure in the Next Millennium’, Peekskills Hospital,
Peekskills, NY. March 12, 2001.
Cardiology Grand Rounds: ‘Emerging Therapies in Heart Failure’, St. John’s Hospital, Elmhurst, NY.
March 2, 2001.
Department of Surgery Grand Rounds: ‘Surgical Modalities for the Treatment of Heart Failure’, Saint
Vincent’s Catholic Medical Centers, New York, NY. February 14, 2001.
Cardiology Grand Rounds ‘Emerging Therapies in Heart Failure’, Saint Vincent’s Catholic Medical Center,
New York, NY. January 11, 2001.
Cardiology/Cardiac Surgery Grand Rounds: ‘LVADs and the Long-term Management of Heart Failure
Patients’, Saint Vincent’s Catholic Medical Center, New York, NY. December 2000.
Department of Medicine Section of Geriatric Medicine: ‘Congestive Heart Failure in the Elderly’, Saint
Vincent’s Catholic Medical Center, New York, NY. June 20, 2000.
Cardiology Grand Rounds: ‘Diastolic Dysfunction – Mechanisms and Clinical Implication’, Saint
Vincent’s Catholic Medical Center, New York, NY. June 16, 2000.
Department of Medicine Grand Rounds: ‘Congestive Heart Failure’, Brookdale Hospital, Brooklyn, NY. June
9, 2000.
Department of Anesthesia Grand Rounds: ‘Heart Failure in the Next Millennium’, Saint Vincent’s Catholic
Medical Center, New York, NY. June 7, 2000.
Department of Medicine: ‘Congestive Heart Failure’, Saint Vincent’s Catholic Medical Center, New York,
NY. May 26, 2000.
Cardiology Grand Rounds: ‘Diastolic Dysfunction - Mechanism and Clinical Implication’, The New York
Hospital Medical Center of Queens, Flushing, NY. May 24, 2000.
American Heart Association 26th Annual Cardiac Scientific Teaching Day, Sullivan County - ‘Congestive
Heart Failure: Diagnosis and Management Update’. May 12, 2000.
Department of Medicine Grand Rounds: ‘Heart Failure: New Concepts and their Therapeutic Implications’,
Millord Fillmore Hospital Center, Buffalo, NY. May 1999.
Symposium on Heart Failure, Basic and Clinical Aspects: ‘Acute and Long-Term Management of Diastolic
Dysfunction’, American Heart Association, New York, NY. May 1999.
Department of Medicine Grand Rounds: ‘Heart Failure in the Next Millennium’, Our Lady of Mercy Hospital,
Bronx, NY. December 1999.
Department of Surgery Grand Rounds: ‘Advances in Cardiovascular Diseases’, UMDNJ - NJ Medical School,
Newark, NJ. December 1998.
Cardiology Grand Rounds: ‘Evolving Paradigms in Heart Failure’, Mountainside Hospital, Mountainside, NJ.
November 1998.
Page 15 of 40
Department of Medicine Grand Rounds: ‘Novel Therapeutics in Heart Failure’, Clara Mass Hospital,
Belleville, NJ. June 1998.
Department of Medicine Grand Rounds: ‘Novel Therapeutics in Heart Failure’, Bergen Pines Hospital, Bergen
Pines, NJ. May 1998.
Department of Medicine Grand Rounds: ‘Heart Failure in the Next Millennium’, Columbus Hospital, Newark,
NJ. March 1998.
Department of Medicine Grand Rounds: ‘Paradoxes and Paradigms in Heart Failure - Therapeutic
Implications’, Beth Israel Medical Center, Newark, NJ. March 1998.
Department of Medicine Grand Rounds: ‘Lasers, Shavers and Cutters - New Modalities in Interventional
Cardiology’, Cabrini Medical Center, New York, NY. September 1997.
Department of Medicine Grand Rounds: ‘Heart Failure-Paradoxes and Paradigms’, UMDNJ - NJ Medical
School, Newark, NJ. April 1997.
Cardiology Grand Rounds: ‘New Models in Heart Failure - Apoptosis and Beta Blockade’, UMDNJ - NJ
Medical School, Newark, NJ. February 1997.
Cardiology Grand Rounds: ‘New Models in Heart Failure - Apoptosis and Beta Blockade’, Englewood
Hospital, Englewood, NJ. November 1996.
Department of Medicine Grand Rounds: ‘New Models in Heart Failure - Apoptosis and Beta Blockade’,
Cabrini Medical Center, New York, NY. October 1996.
Cardiology Grand Rounds: ‘Congestive Heart Failure - Pathophysiologic Mechanisms’, St. Luke's/Roosevelt
Hospital Center, New York, NY. March 1996.
Department of Medicine Grand Rounds: ‘Clinical Trials in Heart Failure’, St. Luke's Hospital Center, New
York, NY. April 1995.
Department of Medicine Grand Rounds: ‘Congestive Heart Failure - SAVE, SOLVD and Beyond’, Roosevelt
Hospital Center, New York, NY. May 1995.
Department of Medicine Grand Rounds: ‘Congestive Heart Failure – SAVE, SOLVD and Beyond’, Cabrini
Medical Center, New York, NY. May 1995.
Department of Medicine Grand Rounds: ‘Current Management of Congestive Heart Failure’, Saint Vincent’s
Catholic Medical Center, Staten Island, NY. April 1995.
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
Mentoring Medical Students - SMDEP Program
Department of Medicine, Cardiology Training Program:
3 Year Cardiology Training Curriculum Training at three sites.
Core Curriculum, Daily Cardiac Conferences
Second & Third Year Medical Students Lecture Series
Cardiovascular Disease, Heart Failure, Acute MI, ECG
Cardiology Fellowship Program:
Core Lecture Series: Cardiac Catheterization – Introduction and
Hemodynamics, Myocardial Rupture, Exercise Physiology,
Thrombolysis in Acute MI, Primary PTCA in Acute MI, Pacemakers
Page 16 of 40
2007 - Present
2004 - Present
2004 - Present
1996 - 1999
Saint Vincent’s Catholic Medical Center
Department of Medicine, Housestaff Lecture Series: Shock, Pulmonary
Edema, Heart Failure, Board Review Cardiology Fellowship Program
Core Lecture Series: Heart Failure, Device Therapy, Shock
NY Medical College
Department of Medicine, Third Year Medical Students: Cardiovascular
Disease: Heart Failure
2000 - 2004
1999 - 2004
B. Research Training
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
Cardiovascular Training Program: Cardiology Fellows
2013-2014
Christopher DiGiorgio, Puneet Ghayal, Atish Mathur, Nandan Thirunahari, Hayder Hashim, Adam Raskin,
Ifad Rahman, Venkata Boppana, Saurabh Kapoor, Fatima Samad
2012-2013
Oussama Lawand, Wojciech Rudzinski, Eyad Alhaj, Christopher DiGiorgio, Puneet Ghayal, Atish Mathur,
Nandan Thirunahari, Hayder Hashim, Adam Raskin, Ifad Rahman, Samir Garyali, Nicholas Kalayeh
2011-2012
Rajiv Patel, Alfonso Waller, Santosh Varkey, Arthur Rusovici, Oussama Lawand, Wojciech Rudzinski,
Eyad Alhaj, Christopher DiGiorgio, Puneet Ghayal, Atish Mathur, Abed Dehnee, Ali Nasur
2010-2011
Aarti Patel, Michael Kasper, Daniel Tysvine, Rajiv Patel, Alfonso Waller, Santosh Varkey, Arthur
Rusovici, Oussama Lawand, Mitul Gandhi, Wojciech Rudzinski
2009-2010
Brijesh Patel, Victor Mazza, Monica Sanchez-Ross, Aarti Patel, Michael Kasper, Daniel Tysvine, Rajiv
Patel, Alfonso Waller, Santosh Varkey, Arthur Rusovici
2008-2009
James Maher, Pallavi Peter, David Sedaghat, Gerard Oghlakian, Brijesh Patel, Victor Mazza, Monica
Sanchez-Ross, Aarti Patel, Michael Kasper, Daniel Tysvine
2007-2008
Bernard Kim, Steve Tsai, Ramzan Zakir, James Maher, Pallavi Peter, David Sedaghat, Gerard Oghlakian,
Brijesh Patel, Victor Mazza, Monica Sanchez-Ross
2006-2007
Vivek Dhruva, Ather Anis, Jesus Mendiolaza, Samir Ahuja, Bernard Kim, Steve Tsai, Ramzan Zakir, James
Maher, Pallavi Peter, David Sedaghat
2005-2006
Jason Levine, David Manela, Vivek Dhruva, Bernard Kim, Steve Tsai, Samir Ahuja, Ather Anis, Ramzan
Zakir, Jesus Mendiolaza, James Maher
2004-2005
Jennifer Zimmer, Amir Choudhry, Kingsley Okoroafor, Jason Levine, David Manela, Vivek Dhruva, Samir
Ahuja, Ather Anis, Jesus Mendiolaza
Saint Vincent’s Catholic Medical Center
Cardiology Research Program
Page 17 of 40
1999-2004
Babu Doddapaneni, John Liuzzo, Sunandan Pandya, Zahir Rahman, Lance Reinherz, David D’Agate,
Salvatore Mannino, Nirav Shah, Damian Kurian, Frank Tamburrino, Igor Tubin, Apostolos Voudouris,
Vikram Mandadi, Gary Bronstein, Gennie Yee
Pre Doctoral Students:
None
CLINICAL RESPONSIBILITIES:
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
Department of Medicine
Attending, Cardiac Care Unit (3 months/year)
Attending, Cardiac Catheterization Lab (4 months/year)
Attending, Heart Failure Service (12 months/year)
Attending, Cardiac Care Unit (5 months/year)
Attending, Cardiology Consult Service (2 months/year)
Attending, Cardiac Catheterization Lab (12 months/year)
Attending, Heart Failure Service (12 months/year)
Saint Vincent’s Catholic Medical Center
Department of Medicine
Attending, Heart Failure Service (12 months/year)
Attending, Cardiac Catheterization Lab (12 months/year)
Attending, Cardiac Care Unit (2 months/year)
Attending, Cardiology Consult Service (1 month/year)
Weiler Hospital, Albert Einstein College of Medicine
Department of Medicine
Attending, Coronary Care Unit (2 months/year)
Attending, Cardiology Consult (3 months/year)
St. Luke’s/Roosevelt Hospital
Department of Medicine
Attending, Medical Ward (2 months/year)
Attending, Resident morning report (1 month/year)
Attending, Cardiac Care Unit (1 month/year)
Attending, Telemetry Unit (1 month/year)
Attending, Heart Failure Service (12 months/year)
Attending, Echocardiography Laboratory (5 months/year)
2004 - Present
1995 - 1999
1999 - 2004
1994 - 1995
1992 - 1994
1993 - 1994
GRANT SUPPORT:
A. Principal Investigator
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
2004 - Present
CUPID CELL 004: Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac
Disease Phase 2/3 (CUPID Phase 2/3 Trial). A Phase 2/3, Double-Blind, Placebo-Controlled, Multicenter,
Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR
(AAV1/SERCAa) in Subjects with Heart Failure.
Sponsor: Celladon Corporation
$132,000
2012 - Present
PRESERVE: A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intracoronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in
Patients with Acute Myocardial Infarction.
Sponsor: Amorcyte, Inc
$125,000
2012 - Present
Page 18 of 40
GeNO-P-2010-002: A Phase 2, Open-Label, Dose-Escalation Study in Subjects with Pulmonary Arterial
Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary
Fibrosis, (PH-IPF WHO Group 3) Using Inhaled NITROsyl™.
Sponsor: GeNO LLC
$28,000
2012 - Present
ASTRONAUT: A multicenter, randomized, double-blind, parallel, group, placebo-controlled study to
evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and
mortality when initiated early after hospitalization for acute decompensated heart failure.
Sponsor: Novartis
$18,000
2010 - 2012
FIX-HF-5B: Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects with Heart
Failure with Ejection Fraction between 25% and 45% and NYHA Class III Symptoms.
Sponsor: Impulse Dynamics (USA), Inc.
$35,000
2011 - Present
ALECARDIO:
Purpose: A Phase III study assessing the effects on cardiovascular risk in patients with a recent Acute
Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D).
Sponsor: Hoffman-LaRoche
$13,000
2012 - Present
EXAMINE: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects
with Type 2 Diabetes and Acute Coronary Syndrome.
Sponsor: Takeda Global Research & Dev. Center, Inc. $12,000
2012 - Present
CK-LX3401 - THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class
III/IV Cardiac Patient Evaluation.
Sponsor: Cardiokine Biopharma, LLC
$20,000
2010 - 2012
RELAX AHF: A Phase II/III, Multicenter Randomized, Double-blind Placebo-Controlled Study to
Evaluate the Efficacy and safety of Relaxin in Subjects with Acute Heart Failure.
Purpose: Relaxin is a potent vasodilator hormone normally released during pregnancy. This study will
access safety, hemodynamic and symptomatic effect of IV Relaxin in patients for ADHF.
Sponsor: Corthera Inc.
$13,000
2009 - Present
CUPID CELL 001: Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac
Disease (CUPID Trial). A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV
I/SERCA2a) in Subjects with Heart Failure Divided into Two Stages: Stage One Open-Label, Sequential
Dose-Escalation Cohorts and Stage Two Randomized, Double-Blind, Placebo-Control, Parallel Cohorts.
Sponsor: Celladon Corporation
$65,000
2009 - Present
RED-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and
Safety of Darbeopetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with
Symptomatic Left Ventricular Systolic Dysfunction and Anemia.
Purpose: To assess the safety and efficacy of Darbepoetin alfa on mortality and morbidity in heart failure
subjects with symptomatic systolic dysfunction and anemia.
Sponsor: Amgen
$75,000
2008 - Present
RESPECT: The Randomized Evaluation of Recurrent Stroke comparing PFO Closure to Established
Current Standard of Care Treatment.
Purpose: To evaluate the efficacy of the AMPLATZER percutaneous closure device vs. medical therapy in
patients with PFO in the prevention of recurrent embolic stroke.
Sponsor: AGA Medical
$40,000
2007 - 2009
PFO Access: Patent Foramen Ovale Closure with the Amplatzer PFO Occluder in patients with Recurrent
Cryptogenic Stroke (due to presumed paradoxical embolism through a patent foramen ovale) Who have
Failed Conventional Therapy.
Sponsor: AGA Medical Corporation
$11,000
2007 - Present
Page 19 of 40
New Jersey Healthcare Initiatives Expecting Success: Excellence in Cardiac Care ‘Improving treatment
and outcomes for minority patients hospitalized for heart failure.’
Sponsor: Peer Review Grant Robert-Wood Johnson Foundation - UMDNJ - NJ Medical School.
$180,000
2007 - 2008
ASPIRE: A 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel group study
to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling
in high risk post-acute myocardial infarction patients when added to optimized
standard therapy.
Sponsor: Novartis.
$55,000
2007 - 2009
ARIES-3: A Phase 3, Long-term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in
Subjects with Pulmonary Hypertension.
Sponsor: Gilead Science, Inc.
$12,000
2007 - 2008
ASCEND: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of
Nesiritide in Subjects With Decompensated Heart Failure.
Sponsor: SCIOS, Inc.
$260,000
2007 - 2010
PROTECT: A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute
heart failure syndrome and renal impairment who are hospitalized for volume overload and require
intravenous diuretic therapy.
Sponsor: NovaCardia.
$72,000
2006 - 2009
Double-Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for
Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction.
Sponsor: Medical School Grant J&J Foundation.
$12,000
2006 - 2008
PST 274: Safety and Tolerability of IV PST2744 in Adults with Chronic Heart Failure: A Phase I-II
Study. Sponsor: Sigma-Tau Research, Inc. $30,000
2005 - 2006
STAT-MI Trial: ST-Elevation Analysis Using Wireless Technology: Achieving the Golden Hour in
Acute Myocardial Infarction.
Purpose: To describe the efficacy of field based wireless ECG transmission in the treatment of STEMI and
their impact across gender and racial differences.
Sponsor: Medtronic/Verizon
$200,000
2005 - Present
MOMENTUM: Multi-Center trial of the Orqis Medical CRS for the ENhanced Treatment of CHF
Unresponsive to Medical Therapy.
Sponsor: Orqis TM Medical.
$160,000
2005 - 2008
ECLIPSE: Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of
Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects with Heart Failure. Eclipse Study.
Sponsor: Otsuka Maryland Research Institute, Inc. $44,000
2005 - 2006
Department/Division Investigator Initiated Funded Research
Evaluation of the association between Gender and Interventricular Mechanical Delay in patients that are
candidates for CRT Implantation.
PI: Sandhya Dhruvakumar, MD / Co-PIs: Marc Klapholz, MD, Ursula Blanc, MBBS, BA, Oussama
Lawand, MD, Victor Mazza, MD, Malgorzata Mysliwiec, MD, Wojciech Rudzinski, MD.
2012 - Present
Telomere Dynamics in Humans.
Page 20 of 40
PI: Abraham Aviv, MD / Co-PIs: Masayuki Kimura, MD, Ph.D, Carol Singer-Granick, MD, Lily Daniali,
MD, Mark S. Granick, MD, Utz Herbig, Ph.D, Soyeon Kim, PhD, Sanjeev Sabharwal, MD, Justin Sambol,
MD, Edwin Deitch, MD, Paul D. Langer, MD, Marc Klapholz, MD, Sandhya Dhruvakumar, MD, Puneet
Ghayal, MD, Victor Mazza, MD, Asha Bale, MD.
2012 - Present
The Effects of Extracorporeal Shockwave Lithotripsy on Pacemakers and Implantable Cardioverter
Defibrillators.
PI: Victor J. Mazza, MD / Co-PIs: Marc Klapholz, MD, Alfonso Waller, MD,
Wojciech Rudzinski, MD, Ph.D, Ursula Blanc, MBBS MPH, Victoria Chima, MBBS, BA,
Santosh Varkey, MD.
2009 - 2011
The Effects of High Power Potassium-Titanly-Phosphate Laser Photoselective Vaporization Prostatectomy
on Pacemakers and Implantable Cardioverter Defibrillators
PI: Victor Mazza, MD / Co-PI: Marc Klapholz, MD.
2009 - 2011
Assessing the interaction between liver disease and cardiovascular structure and function.
PI: Marc Klapholz, MD / Co-PIs: Christine Gerula, MD, Baburao Koneru, MD, Yonatan Faiwiszewski,
BA, Wojciech Rudzinski, MD., Ph.D, Richard Schmidt, BA, Alfonso Waller, MD, Ursula Blanc, MBBS
MPH.
2008 - Present
Phenotypic and Proteomic study in low vs. normal EF African-American hypertensive non-ischemic heart
failure patients.
PI: Marc Klapholz, MD / Co-PIs: James M. Maher, MD, Alfonso Waller, MD, Santosh Varkey, MD,
Edo Kaluski, MD, Rajiv Patel, MD, Ryann Mattessich, APN C, Ursula Blanc, MBBS MPH.
2006 - Present
Osteopontin Levels Before and After Spironolacton Administration in patients with Low Ejection Fraction
Heart Failure on Hemodialysis.
PI: Marc Klapholz, MD / Co-PI: Monica Sanchez-Ross, MD.
2006 - 2009
Utility of rest and stress myocardial contrast echocardiography in intensive care units for evaluating
coronary artery disease in patients with non-ST elevation myocardial infarction.
PI: Marc Klapholz, MD / Co-PI: Ather Anis, MD.
2005 - 2007
Saint Vincent’s Catholic Medical Center
Total Funding:
$1,278,000
2000 - 2004
Vasodilator Induced Stress in Concordance with Adenosine (VISION-301).
Sponsor: King Pharmaceutical, Inc.
2004
Multicenter, Randomized, Double-Blind Parallel Group, Placebo Controlled Study to Assess the Effects of
Immune Modulation Therapy on Mortality and Morbidity in Patients with Chronic Heart Failure.
Sponsor: Vasogen, Inc.
2004
Safety and Tolerability of PST2744 in Adults with Chronic Heart Failure: A Phase with I-II Study.
Sponsor: Sigma-Tau, Inc.
2004
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy
and Safety of Oral Tolvaptan in Subjects Hospitalized with Worsening Congestive Heart Failure.
Sponsor: Otsuka Maryland Research Institute, Inc.
2004
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Efficacy,
Safety and Tolerability of Tezosentan in Patients with Acute Heart Failure.
Sponsor: Actelion Pharmaceuticals Ltd.
2004
Double-Blind, Randomized, Placebo-Controlled Trial of Natrecor in Patients Hospitalized for
Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction.
Page 21 of 40
Sponsor: Scios, Inc. and Daxor Corporation.
2004
The Clinical, Hemodynamic and Endothelial Cell Response to Biventricular Pacing in Patients with
Symptomatic Heart Failure. Sponsor: Fourjay Foundation Grant.
2003
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Oral
Tolvaptan in Patients with Hyponatremia. Sponsor: Otsuka Maryland Research Institute, Inc. 2003
Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of
Oxypurinol Added to Standard Therapy in Patients with NYHA Class III-IV Congestive Heart Failure.
Sponsor: Cardiome Pharma Corp.
2003
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Pilot Study Evaluating the Efficacy and Safety
of YM087 in Patients with Decompensated Chronic Heart Failure.
Sponsor: Yamanouchi Pharma America, Inc.
2003
Heart Failure Therapy: Clinical and Endothelial Responses. Unrestricted Education Grant Funds. 2003
Double Blind, Randomized, Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated
Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction.
Unrestricted Education Grant Funds.
2003
A Phase II-III Prospective, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of
Oxypurinol Added to Standard Therapy in Patients with NYHA Class III-IV Congestive Heart Failure (OPTCHF). Sponsor: Cardiome Pharma Corporation.
2003
Acute Decompensated Heart Failure National Registry (ADHERE). Sponsor: Scios, Inc. 2003
Organized Program to Initiate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZEHF). Sponsor: GlaxoSmithKline.
2003
Phase II, Double-Blind, Randomized, Exploratory, Placebo-Controlled Study of the Efficacy, Safety and
Tolerability of MCC-135 Comparing QD vs. BID Doses in Subjects with Congestive Heart Failure, NYHA
Class II/III (01-02-TL-MCC-135-001).
Sponsor: Takeda Pharmaceuticals North America, Inc.
2003
Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Impact of Subcutaneous (SC)
Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects with Symptomatic Congestive Heart Failure
(CHF) and Anemia.
Sponsor: Amgen, Inc.
2003
A-Heft (African-American Heart Failure Trial). Placebo Controlled Trial of BiDil Added to Standard Therapy
in African-American Patients with Heart Failure.
Sponsor: NitroMed, Inc.
2003
Clinical and Economic Effectiveness of a Technology-Driven Heart Failure Monitoring System. The ALERE
Study. Sponsor: HCFA.
2003
Randomized, Multicentered Evaluation of Intravenous Levosimendan Efficacy versus Placebo in the Short
Term Treatment of Decompensated Chronic Heart Failure (REVIVE).
Sponsor: MDS Pharma Services.
2002
Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVD-HF): Nesiritide
Myocardial Protection Study.
Sponsor: Scios, Inc.
2002
Page 22 of 40
Randomized, Two-Arm Crossover Study of Safety, Tolerability, and Myocardial Perfusion Imaging of
MRE0470 vs. Adenosine. Sponsor: King Pharmaceuticals, Inc.
2002
A 5-Day, Double-Blind, Placebo-Controlled, Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy
and Safety in Patients with Euvolemic or Hypervolemic Hyponatremia. Protocol 1025-006.
Sponsor: Yamanouchi.
2002
A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CL-1025) to assess Efficacy
and Safety in Patients with Euvolemic or Hypervolemic Hyponatremia. Protocol 1025-007.
Sponsor: Yamanouchi.
2002
A 12-week, Open-Label Extension to Protocol 1025-006 and Protocol 1025-007 to Evaluate the Safety and
Efficacy on Patients with Euvolemic or Hypervolemic Hyponatremia. Protocol 1025-011.
Sponsor: Yamanouchi.
2002
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study to
Evaluate the Effects of Oral Administration Tolvaptan (OPC-41061) when Compared to Furosemide
(VICTOR). Sponsor: Otsuka Pharmaceuticals.
2001
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study to Evaluate the
Effects of Tolvaptan (OPC-41061) on the Chronic Outcomes of Patients with Congestive Heart Failure
(VITAL). Sponsor: Otsuka Pharmaceuticals.
2001
Prospective Randomized Outcomes Study of Acutely Decompensated CHF Treated Initially in Outpatients
with Natrecor. The PROACTION Trial. Sponsor: SCIOS.
2001
Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose Comparative Study of the Efficacy,
Tolerability and Safety of MCC-135 in Subjects with Chronic Heart Failure, NYHA Class II/III. Sponsor:
Mitsubishi-Tokyo Pharmaceuticals and Mitsubishi Chemical America, Inc.
2001
Placebo-Controlled Trial of Bidil Added to Standard Therapy in African-American Patients with Heart Failure
(A-HeFT). Sponsor: NitroMed, Inc.
2001
Phase III, Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study of Oral
Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects (ESSENTIAL), Protocol No. MY-021.
Sponsor: Myogen, Inc.
2001
Phase III, Randomized, Double-Blind, Parallel Group, Efficacy Study of Enoximone Plus Metoprolol or
Metoprolol Alone vs. Placebo in Advanced Chronic Heart Failure Subjects Who were Previously B-blocker
Treatment Failures. Sponsor: Myogen, Inc.
2000
Multicenter, Double-Blind Placebo Controlled Phase II/III Study of the Effect of Recombinant Human
Tumor Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR:Fc) on Clinical Improvement in Patients
with Chronic Heart Failure. Sponsor: Immunex Corporation.
2000
Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study evaluating the effects of different
doses of LU 135252 on left ventricular dimensions, function, and left and right ventricular mass,
neurohormone levels, and symptoms in patients with advanced congestive heart failure.
Sponsor: Knoll BASF Pharma.
2000
Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events - (OVERTURE), Multicenter
Trial in Class II-III Heart Failure. Sponsor: Bristol-Myers Squibb.
2000
The Greater New York Heart Failure Consortium Registry on Diastolic Dysfunction: Epidemiologic,
Clinical, Echocardiographic and Hemodynamic Variables.
Marc Klapholz, MD, Principle Investigator.
2000
Page 23 of 40
University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Total Funding:
$750,000
1995 - 1999
Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Ro 47-0203 (Bosentan) on the
Morbidity and Mortality of Patients with Chronic Heart Failure (Enable-2). Sponsor: Actelion Corporation.
1999
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the effect of Carvedilol on
Mortality in Patients with Severe Congestive Heart Failure. Sponsor: Smith Kline Beecham Pharmaceuticals.
1999
Multicenter, Double-Blind Placebo Controlled Phase II/III Study of the Effect of Recombinant Human
Tumor Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR:Fc) on Clinical Improvement in Patients
with Chronic Heart Failure. Sponsor: Immunex Corporation. 1999
Open label, Dose-Titration and Maintenance, Pilot Efficacy and Safety Study of YM087 in SIADH Patients
with Euvolemic Hyponatremia or CHF Patients with Hypervolemic Hyponatremia. Sponsor: Parke Davis
Pharmaceutical Research. 1999
Randomized Double-Blind, Multicenter, Placebo-Controlled Study of the IV dose Response of YM087 (CI1025) on Cardiopulmonary Hemodynamics in Patients with Class III/IV Heart Failure. Sponsor: Parke Davis
Pharmaceutical Research. 1999
An Exploratory Study of YM087 (CI-1025) Administered Intravenously to Assess the Safety and Efficacy
in Patients with Acute Decompensated Heart Failure.
Sponsor: Parke Davis Pharmaceutical Research. 1999
Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events - Overture Trial, Multicenter
Trial in Class II-III Heart Failure. Sponsor: Bristol-Myers Squibb. 1999
Multicenter Double-Blind Placebo Controlled Study to Evaluate the Effect of OPC-41061 on the Acute and
Chronic Outcomes of Hospitalized Patients with Heart Failure. Sponsor: Otsuka Pharmaceuticals. 1999
Randomized Double-Blind Placebo Controlled Multicenter, Dose Ranging Study to Assess the Efficacy,
Tolerability and Safety of SB 217242 (Endothelin Receptor Antagonist) in Patients with Stable NYHA Class
II-III Congestive Heart Failure. Sponsor: Smith Kline Beecham Pharmaceuticals. 1998
Comparison of the Acute Hemodynamic Effects and Safety of the Endothelin Receptor Antagonist BMS193884 versus Placebo in Subjects with Heart Failure. Sponsor Bristol-Myers Squibb. 1998
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the effect of Carvedilol on
Mortality in Patients with Severe Congestive Heart Failure. Sponsor: Smith Kline Beecham Pharmaceuticals.
1998
Inhibition of Metalloprotease By BMS-186716 In a Randomized Exercise and Symptoms Study in Subjects
With Heart Failure (IMPRESS). Sponsor: Bristol-Myers Squibb. (028). 1997
The Pharmacokinetics and Pharmacodynamics of BMS-186716 In Congestive Heart Failure Patients and
Matching Controls. Sponsor: Bristol-Myers Squibb (021). 1997
Phase 3, Randomized, Double Blind, Dose Response, Positive Control Evaluation of the Efficacy and Safety of
Toborinone (OPC-18790) in the Treatment of Patients With Heart Failure. Sponsor: Otsuka America
Pharmaceutical. 1997
Double Blind, Randomized, Placebo Controlled Study to Assess the Effects of Ro 47-0203 (Bosentan) on the
Clinical Status of Patients with Advanced Heart Failure and the Pharmacokinetics of Ro 47-0203. Sponsor
Hoffman-LaRoche. 1996
Page 24 of 40
Multicenter, Randomized, Double-Blind, Placebo Controlled, Sequential Design Study of the Acute
Hemodynamic Effects and Safety of the Dual Metalloprotease Inhibitor BMS-186716 in the Treatment of
Heart Failure. Sponsor: Bristol-Myers Squibb. 1996
Multicenter, Randomized Study of the Long Term Hemodynamic Effects and Safety of the Dual
Metalloprotease Inhibitor BMS-186716 in the Treatment of Heart Failure. Sponsor: Bristol Myers Squibb.
1996
Evaluation of the Safety/Tolerability of Long-Term Treatment with the DMP Inhibitor BMS-186716 or
Lisinopril in Subjects with Heart Failure. Sponsor: Bristol-Myers Squibb. 1996
An Open Label Evaluation of Carvedilol in Patients with Chronic Congestive Heart Failure NYHA Class II-IV.
Sponsor: SmithKline Beecham Pharmaceuticals.
1996
St. Luke's/Roosevelt Hospital Center, New York, NY
Total Funding:
$280,000
1992 - 1994
An Open Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure.
Sponsor: Otsuka Pharmaceuticals.
1992-1995
A Randomized Multiple Dose Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart
Failure. Sponsor: Otsuka Pharmaceuticals.
1992-1995
Evaluation of the Hemodynamic Effects and Safety of the Angiotensin II Antagonist SR47436 (BMS 186295).
Sponsor: Bristol-Myers Squibb Pharmaceuticals.
1992-1995
A Six Month Double-Blind Multicenter Comparison of Oral Carvedilol b.i.d. withPlacebo in Patients with
Congestive Heart Failure, NYHA Class II-IV.
Sponsor: SmithKline Beecham Pharmaceuticals.
1992-1995
A Six Month Double-Blind Multicenter Comparison of Oral Carvedilol b.i.d. with Placebo in Patients with
Severe Congestive Heart Failure, NYHA Class III-IV.
Sponsor: SmithKline Beecham Pharmaceuticals.
1992-1995
A Twelve-month Double-Blind Multicenter Comparison of Oral Carvedilol b.i.d. with Placebo in Patients with
Mild Congestive Heart Failure, NYHA Class II.
Sponsor: SmithKline Beecham Pharmaceuticals.
1992-1995
A One Year, Open label, Multicenter, Safety Study of Twice Daily Oral Carvedilol in Patients with NYHA
Class I-IV Congestive Heart Failure Protocol.
Sponsor: SmithKline Beecham Pharmaceuticals.
1992-1995
Efficacy and Safety of Moderate-Dose Milrinone in Combination with Dobutamine, Compared with
Dobutamine Alone, in the Treatment of Heart Failure Secondary to Myocardial Infarction. Sponsor: Sanofi
Winthrop Pharmaceuticals.
1992-1995
A Multinational Randomized, Open, Parallel, Group Comparison of the Effects of Chronic FLOLAN Therapy
Plus Conventional Therapy to Conventional Therapy Alone on Survival in Patients with Severe Refractory
Congestive Heart Failure. Sponsor: Burroughs Wellcome Co.
1992-1995
B.
Co-Investigator
New Jersey Medical School - University of Medicine & Dentistry of New Jersey
Page 25 of 40
2004 - 2009
GS-US-259-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of
Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who
Undergo Percutaneous Coronary Intervention with Incomplete Revascularization
PI: Edo Kaluski, MD / Co-PI: Marc Klapholz, MD
Sponsor: Gilead Inc.
$21,000
2012 - Present
LAPTOP-HF: Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study.
Purpose: First-in-man randomized study evaluating the efficacy of direct, continuous and wirelessly
transmitted left atrial pressures (LAP) in combination with dynamic treatment algorithims. PI: James
Maher, MD/ Co-PI: Marc Klapholz, MD.
Sponsor: St. Jude Medical
$108,000
2011 - Present
PATENT-1: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate
the efficacy and safety of oral BAY 63-12521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with
symptomatic Pulmonary Arterial Hypertension (PAH).
Purpose: To study the intermediate term effects of this direct stimulation of guanylate cyclase which
mediates vasorelaxation and inhibition of platelet aggregation. PI: James Maher, MD / Co-PI: Marc
Klapholz, MD.
Sponsor: Bayer Healthcare AG
$8,000
2010 - 2012
PATENT-2: Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability
of oral BAY 63-12521 (1 mg, 1.5 mg, 2.5 mg tid) in patients with symptomatic Pulmonary Arterial
Hypertension (PAH). PI: James Maher, MD / Co-PI: Marc Klapholz, MD.
Sponsor: Bayer Healthcare AG
$7,000
2010 - 2012
CARDIOKINE: CK-LX2401: Multicenter, randomized, double-blind, placebo-controlled, parallel group,
efficacy and safety study to evaluate the effects of oral administration of lixivaptan in patients with
congestive heart failure.
PI: James M. Maher, MD / Co-PI: Marc Klapholz, MD
Sponsor: Cardiokine Biopharma, LLC
$20,000
2010 - 2012
ROCHE Dal-Outcomes: Randomized, Double-blind Study Assessing the Effect of Dalcetrapib on
Cardiovascular Mortality and Morbidity in Patients with Recent Acute Coronary Syndrome.
Purpose: To access the effect of RO4607381 (Dalcetrapib 600 mg daily) on cardiovascular mortality and
morbidity in clinically stable patients with a recent Acute Coronary Syndrome. PI: Edo Kaluski, MD / CoPI: Marc Klapholz, MD.
Sponsor: Hoffman-LaRoche
$68,000
2008 - 2011
TRILOGY ACS Study: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS)
Subjects with Unstable Angina/Non-ST Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically
Managed. PI: Edo Kaluski, MD / Co-PI: Marc Klapholz, MD.
Sponsor: Eli Lilly & Company
$15,000
2008 - 2009
TRA-CER: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Efficacy of SCH 530348 in Subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist for
Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER).
PI: Edo Kaluski, MD / Co-PI: Marc Klapholz, MD.
Sponsor: Schering Plough
$82,000
2008 - 2011
PLATO: A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140
Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute
Coronary Syndromes (ACS) PLATO. PI: Edo Kaluski, MD / Co-PI: Marc Klapholz, MD.
Sponsor: AstraZeneca.
$71,475
2007 - 2012
WARCEF: Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction.
PI: Christine Gerula, MD / Co-PI: Marc Klapholz, MD.
Sponsor: NIH.
$62,000
2006 - Present
Page 26 of 40
Weiler Hospital, Albert Einstein College of Medicine
PI: E.S. Monrad, MD
1994 - 1995
Randomized, Double-Blind, Placebo Controlled Study of the Effects of MK-383 on Cardiac Outcomes in
Patients Undergoing Percutaneous Transluminal Coronary Angioplasty.
PI: Thierry LeJemtel, MD
1989 - 1991
Evaluation of the Efficacy and Safety of Ramipril vs. Placebo in Patients with Congestive Heart Failure.
Double-Blind, Placebo-Controlled Study of the Effects of RGW 2938 on Exercise Performance In Ambulatory
Heart Failure Patients.
Open-Label Study Following Treatment with RGW 2938 in Patients with Congestive Heart Failure.
Open-Label Study of the Acute Administration and Oral Titration of OPC 8212 in Heart Failure.
Open Label Study of the Chronic Administration of OPC-8212 in Patients with Heart Failure.
Dobutamine Lactobionate vs. Dobutamine Hydrochloride in Congestive Heart Failure.
Parallel Evaluation of the Hemodynamic Effects of 3.75, 5, and 30mg of Zofenopril in Patients with Chronic
Heart Failure.
Evaluation of the Acute Hemodynamic Effects of Fosinopril in Patients with Chronic Heart Failure: Long-term
Open-Label Fosinopril Therapy.
Prospective, Three-Month Randomized, Placebo-Controlled Phase III Study of Oral Milrinone In Addition to
Digoxin, Angiotensin-Converting Enzyme Inhibitor and Diuretic Therapies in Patients with Congestive Heart
Failure (Mil-1078).
Phase II, III Clinical Evaluation Study of Patients Receiving Oral Milrinone (Mil-553).
The Long-Term Use of Oral Enoximone In Patients With Chronic Congestive Heart Failure.
An Open-Label Study to Assess the Safety of Pimobendan During Long-Term Treatment in Patients with
Congestive Heart Failure.
St. Luke's/Roosevelt Hospital Center
TIMI 6, Thrombolysis in Myocardial Infarction.
PI: J. Hochman, MD
C.
Pending
1992 - 1993
None
PUBLICATIONS:
A.
Refereed Original Article in Journal
1.
Kishi A, Togo F, Cook DB, Klapholz M, Yamamoto Y, Rapoport DM, Natelson BH. The effects of
exercise on dynamic sleep morphology in health controls and patients with chronic fatigue syndrome.
Physiol Rep. 2013 Nov;1(6):e00152. doi: 10.1002/ph2.152. Epub 2013 Nov 13.
2.
Nakamura T, Schwander S, Donnelly R, Cook DB, Ortega F, Yamamoto Y, Cherniack NS, Klapholz
M, Rapoport D, Natelson BH. Exercise and sleep deprivation do not change cytokine expression
levels in patients with chronic fatigue syndrome. Clin Vaccine Immunol. 2013 Nov;20(11):1736-42.
doi: 10.1128/CVI.00527-13. Epub 2013 Sep 11.
Page 27 of 40
3.
Alhaj E, Alhaj EK, Rahman I, Niazi TO, Berkowitz R, Klapholz M. Uremic cardiomyopathy: an
underdiagnosed disease. Congest Heart Fail. 2013 Jul-Aug;19(4):E40-5. doi:10.1111/chf.12030.
Epub 2013 Apr 25. Review. PMID:23615021.
4.
Alhaj EK, Alhaj NK, Klapholz M. Fibromuscular dysplasia of the renal artery: an under diagnosed
cause of severe hypertension. Int J Cardiol. 2013 Sept 10:167(6):e159-60. doi:10.1016/
j.ijcard.2013.04.189. Epub 2013 May 17. PMID:23684605
5.
Alhaj E, Ahmad US, Niazi OT, Zakhary D, Akhtar M, Zabolotsky A, Oriscello R, Voudouris A,
Kaluski E, Klapholz M. Atypical stress-induced cardiomyopathy: a case series. Acta Cardiology.
2013 April;68(2):222-5. PMID:23705571
6.
Rudzinski W, Waller AH, Rusovici A, Dehnee A, Nasur A, Benz M, Sanchez S, Klapholz M,
Kaluski E. Comparison of efficacy and safety of intracoronary sodium nitroprusside and
intravenous adenosine for assessing fractional flow reserve. Cathether Cardiovasc Interv. 2013
Feb;81(3):540-4. Doi: 10.1002/ccd.24652. Epub 2012 Oct 15. PMID 22961876
7.
Mathur AP, Waller AH, Dhruvakumar S, Mazza V, Gerula C, Maher J, Klapholz M, Kaluski E.
Minerva Cardioangiol. 2012 Dec;60(6):611-28. Review. PMID:23147438
8.
Rusovici A, Ibrahim S, Sood S, Maher J, Gerula C, Kaluski E, Klapholz M. Extensive myocardial
iron deposition in a patient with hepatitis C. Tex Heart Inst J. 2012;39(2):281-283. PMID:2274075
9.
Rudzinski W, Waller A, Rusovici A, Dehnee A, Nasur A, Benz M, Sanchez S, Klapholz M,
Kaluski E. Comparison of efficacy and safety of intracoronary sodium nitroprussid and intravenous
adenosine for assessing fractional flow reserve. Catheter Cardiovasc Interv. 2012 Sept;
7.doi:1.1002/ccd.24652 (Epub ahead of print). PMID:22961876
10. Rudzinski W, Waller AH, Prasad A, Sood S, Gerula C, Samanta A, Koneru B, Klapholz M. New
index for assessing chronotropic response in patients with end stage liver disease who are undergoing
dobutamine stress echocardiography. Liver Transpl. 2012 Mar;18(3):355-60. PMID:22140006
11. Schmidt R, Kasper M, Gerula C, Klapholz M, Haider B, Kaluski E. Intra-aortic balloon pump prior
to noncardiac surgery: a forgotten remedy? J Invasive Cardiol. 2011 Feb;23(2):E-26-30.
PMID:21297214
12. Sanchez-Ross M, Oghlakian G, Maher J, Patel B, Mazza V, Hom D, Dhruva V, Langley D, Palmaro
J, Ahmed S, Kaluski E, Klapholz M. The STAT-MI (ST-Segment Analysis Using Wireless
Technology in Acute Myocardial Infarction) trial improves outcomes. JACC Cardiovasc Interv.
2011 Feb;4(2):222-227. doi: 10.1016/j.jcin.2010.11.007. PMID:21349462
13. Rusovici A, Varkey S, Saeed Q, Klapholz M, Haider B, Kaluski E. Cocaine-induced coronary
thrombosis: what is the optimal treatment strategy. Cardiovasc Revasc Med. 2011 MarApr;12(2):133.e1-6. doi: 10.1016/j.carrev.2010.06.004. Epub 2010 Oct 20. PMID:21421194
14. PMID:21421194Kaluski E, Solanki P, Sanchez-Ross M, Saric M, Randhawa P, Klapholz M, Haider
B, Gerula C. Anteriorly displaced right coronary artery in acute myocardial infarction: what should
every cardiologist know. Cardiovasc Revasc Med. 2011 Jan-Feb;12(1):59-64. doi: 1.1016/j.carrev.2009.09.008. Epub 2010 Oct 20. PMID:21241974
15. Patel A, Waller AH, Rusovici A, Dhruvakumar S, Maher J, Gerula C, Haider B, Klapholz M,
Kaluski E. Routine stress testing after percutaneous coronary interventions. Minerva
Cardioangiol. 2011;59(4):321-30. PMID:21705995.
16. Kaluski E, Waller A, Patel A, Gerula C, Maher J, Haider B, Klapholz M. Clinical Applicability of
Coronary Atherosclerotic Lesion Characterization. Minerva Cardioangiol. 2011;59(3):255-70.
PMID:21516074.
Page 28 of 40
17. Sharma S, Tsyvine D, Maldjian PD, Sambol JT, Lovoulos CJ, Levy G, Maghari A, Klapholz M,
Saric M. An intriguing co-existence: atrial myxoma and cerebral cavernous malformations: case
report and review of literature. Journal of American Society Echocardiography. 2011
Jan;24(1):110.e1-4. Epub 2010 Jul 21. PMID: 20650606
18. Sanchez Ross M, Waller A, Maher J, Haider B, Klapholz M, Kaluski E. Aspirin for the Prevention
of Cardiovascular Morbidity. Panminerva Medica. 2010 August;101(4):205-214. Review.
PMID:21030934
19. Patel B, Kats Y, Saric M, Maldjian PD, Klapholz M. An hourglass-type supravalvular aortic
stenosis. Journal of American Coll Cardiology. 2010 Aug 10;56(7):e13. PMID:20688207
20. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Klapholz M, Moser
DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Executive
Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010
Jun;16(6)e1-194. Doi: 10.1016/j.cardfail.2010.04.004. PMID:20610207
21. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. Osteopontin in cardiovascular disease: a
potential therapeutic target. Cardiology in Review. 2010 May-Jun;18(3):125-31. doi:
10.1097/CRD.0b013e3181cfb646. Review. PMID:20395697
22. Kaluski E, Maher J, Gerula C, Tsai S, Randhawa P, Saric M, Oghlakian G, Alfano D, Palmaro J,
Haider B, Klapholz M. Optimizing Primary PCI Beyond “Door to Intervention Time” - Are We
There Yet? Cardiovasc Revasc Med. 2010 April-Jun;11(2):84-90. doi:
10.1016/j.carrev.2009.04.108. PMID:20347797
23. Abraham WT, Anand IS, Klapholz M, Ponikowski P, Scarlata D, Wasserman SM, van Veldhuisen
DJ. Treatment of anemia with darbeopetin alfa in the heart failure. Congest Heart Fail. 2010 MayJun;16(3):87-95.doi:1111/j.1751-7133.2010.00142.x. PMID 20557327
24. Kaluski E, Tsai S, Milo-Cotter O, Klapholz M. “Buddy in jail” or “buried wire” method: a critical
review. Catheter Cardiovasc Interv. 2010 April 1;75(5):814. doi: 10.1002/ccd.22371.
PMID:20146307
25. Solanki P, Gerula C, Randhawa P, Benz M, Maher J, Haider B, Klapholz M, Palmaro J, Alfano
D, Kaluski E. Right coronary artery anatomical variants: where and how? J Invasive Cardiol.
2010 March;22(3):103-106. PMID:20197575
26. Rezaizadeh H, Sanchez-Ross M, Kaluski E, Klapholz M, Haider B, Gerula C. Acute eosinophilic
myocarditis: diagnosis and treatment. Acute Card Care. 2010 March;12(1):31-6.
PMID:20201659
27. Togo F, Natelson BH, Cherniack NS, Klapholz M, Rapoport DM, Cook DB. Sleep is not
disrupted by exercise in patients with chronic fatigue syndromes. Med Science Sports Exerc.
2010 Jan;42(1):16-22. doi: 10.1249/MSS.0b013e3181b11bc7. PMID:20010134
28. Kats Y, Solanki P, Waller AH, Maldjian PD, Hamirani K, Tsai SC, Dhruva V, Klapholz, M, Saric
M. An unusual combination of an anomalous origin of the left coronary artery from the pulmonary
artery (ALCAPA) and a right coronary artery system with two separate ostia from the aorta in an
adult. Echocardiography. 2010 Jan;27(1):E13-7. doi:10.1111/j.1540-8175.2009.01040.x.
PMID:20380659
29. Mongal LS, Salat R, Anis A, Esrig BC, Oz M, Klaphloz M, Maldjian P, Saric M. Enormous right
atrial hemangioma in an asymptomatic patient: a case report and literature review.
Echocardiography. 2009 Sep;26(8):973-976. doi: 10.1111/j.1540-8175.2009.00947.x. Review.
PMID:19968685
Page 29 of 40
30. Kaluski E, Moussa I, Heuser RR, Kern M, Weitz G, Klapholz M, Gerula C. Automated Contrast
Injectors for Angiography: Devices, Methodology and Safety. Catheter Cardiovasc Interv. 2009
Sep1;74(3):459-464. doi: 10.1002/ccd.22029. Review. PMID19405163
31. Kaluski Edo, Gerula Christine, Randhawa Preet, Klapholz Marc. Funneling: enhancing results of
small-vessel stenting. Cardiovasc Revasc Med. 2009 Oct-Dec;10(4):255-258.
doi:10.106/j.carrev.2009.01.004. PMID: 19815174
32. Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM,
Van Veldhuisen DJ. The Safety and Tolerability of Darbepoetin alfa in Patients with Anaemia and
Symptomatic Heart Failure. European Journal of Heart Failure. 2009 Nov;11(11):1071-1077.
doi:10.1093/eurjhf/hfp130. Epub 2009 Oct 8. PMID: 19815661
33. Klapholz Marc. β-Blocker Use for the Stages of Heart Failure. Mayo Clinic Proc. 2009
August;84(8):718-729. doi: 10.4065/84.8.718. Review. PMID: 19648389
34. Kaluski E, Gerula C, Randhawa P, Haider B, Klapholz M. Massive Coronary Perforation and
Shock: From Appropriate Labeling to Appropriate Calls. Acute Cardiac Care. 2009;11(3):181186. doi: 10.1080/17482940903003000. PMID: 19452339
35. Sedaghat D, Zakir RM, Choe J, Klapholz M, Saric M. Cardiac Amyloidosis in a patient with
multiple myeloma: A Case Report and Review of Literature. J Clin Ultrasound. 2009 MarApr;37(3):179-184. doi:10.1002/jcu.20552. Review
36. Oghlakian G, Klapholz M. Vasopressin and Vasopressin Receptor Antagonists in Heart Failure.
Cardiol Review. 2009 Jan-Feb;17(1):10-15. doi: 10:1097/CRD.0b013e318190e72c. Review.
PMID: 19092365
37. Anis A, Maldjian P, Klapholz M. Images in cardiology. Renal cell carcinoma with extension to
the heart. Can J Cardiology. 2008 November;24(11):860. PMID: 18987762
38. Edo Kaluski, Steve Tsai, Marc Klapholz. Coronary stenting with MGuard: First in Man trial. J
Invasive Cardiol. 2008 Oct;20(10):511-515. PMID: 18829994
39. Greenberg Barry, Czerska Barbara, Delgado Reynolds M, Bourge Robert, Zxile Michael R, Silver
Marc, Klapholz Marc, Haeusslein Ernest, Mather Paul, Abraham William T, Neaton James D,
Brown Scott B, Parker, Irene C, Konstam Marvin A, on behalf of the MOMENTUM Investigators
and Coordinators. Effects of Continuous Aortic Flow Augmentation in Patients with Exacerbation
of Heart Failure, Inadequately Responsive to Medical Therapy; Results of the Multi-center Trial of
the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to
Medical Therapy (MOMENTUM). Circulation. 2008 Sept 16;118(12):1241-1249.
PMID:18765394
40. Kaluski E, Alfano D, Randhawa P, Palmaro J, Jones P, Romano K, Dolny-Korasick D, Klapholz
M. Length of Hospital Stay after Percutaneous Coronary Interventions. Journal of Cardiovasc
Nursing. 2008 July-Aug;23(4):345-348. PMID:18596498
41. Maher J, Rivero A, Zaim S, Pappas, PJ, Labropoulos N, Klapholz M, Saric M: Massive Arm
Edema Following Arteriovenous Dialysis Shunt Creation in a Patient with Ipsilateral Permanent
Pacemaker. Journal of Clinical Ultrasound. 2008 Jun;36(5):321-324. PMID:17702018
42. Pullicino PM, Wadley VG, McClure LA, Safford MM, Lazar RM, Klapholz M, Ahmed A,
Howard VJ, Howard G: Factors contributing to global cognitive impairment in heart failure:
results from a population-based cohort. Journal of Cardiac Failure. 2008 May;14(4):290-295.
PMID:18474341
Page 30 of 40
43. Kaluski Edo, Tsai Steve, Klapholz Marc. Coronary stenting with MGuard: from conception to
human trials. Cardiovasc Revasc Med. 2008 Apr-Jun (9)(2):88-94. doi:
10.1016/j.carrev.2007.12.002. Review. PMID: 18486082
44. Oghlakian Gerard and Klapholz Marc. Cardiovascular Complications of Obesity. Current
Respiratory Medicine Reviews. 2008;(4):150-155.
45. Kaluski E, Uriel N, Milo-Coter O, Klapholz M. Nitric oxide synthase inhibitors in cardiogenic
shock: present and future. Future Cardiol. 2008 Mar;4(2):83-189. doi:
10.2217/14796678.4.2.183. PMID:19804295
46. Edo Kaluski, Bunyad Haider, Olga Milo-Cotter, Marc Klapholz. Glycoprotein IIb/IIIa
Inhibitors-Questioning the indications and treatment algorithms. Cardiovasc Revasc Med. 2007
Oct-Dec;8(4):281-288. PMID:18053951
47. Kaluski E, Groothuis A, Klapholz M, Seifart P, Edelman E. Coronary stenting with MGuard:
feasibility and safety porcine trial. J Invasive Cardiol. 2007 Aug;19:326-330. PMID:17712199
48. Dhruva, V. Abdelhadi, S, Anis A, Gluckman W, Hom D, Dougan W, Haider B, Klapholz M. STSegment Elevation Analysis Using Wireless Technology in Acute Myocardial Infarction: the
STAT-MI Trial. Journal of American Coll of Cardiology. 2007 Aug 7;50(6):509-513.
PMID:17678733
49. Kaluski Edo, Hendler Alberto, Klapholz Marc. PCI of the Right Coronary Artery via or under
Struts of Stents Protruding into the Aorta. J Invasive Cardiol. 2007 Jul;19(7):E207-209.
PMID:17620689
50. Patel RJ , Zakir RM, Sethi V, Patel JN, Apovian J. Alexander JC, Klapholz M, Saric M. A Rare
Case of Unrepaired Tetralogy of Fallot with Right Hemitruncus in an Adult. Tex Heart Inst J.
2007 Jun;34(2):250-251. PMID:17622382
51. Tsai S, Klapholz M. Tips and tricks on outpatient initiation and uptitration of beta-blockade in
heart failure. Current Heart Failure Report. 2007 Jun;4(2):110-116. PMID:17521504
52. Mendiolaza J, Baltasar JF, Anis A, Harrison J, Chen F, Klapholz M, Saric M. Left ventricular
non-Hodgkin lymphoma visualized on contrast echocardiography. Journal of Clinical
Ultrasound. 2007 Oct;35(8):462-464. PMID:17373683
53. Zakir Ramzan M, Patel, Rajiv J, Ahuja Samir, Saric Muhamed, Klapholz Marc. Increases in Left
Ventricular Mass is More Pronounced in Low Ejection Fraction versus Normal Ejection Heart
Failure. Journal of Cardiac Failure. 2006; 12(6): S28.
54. Levine JC, Sedaghat D, Patel B, Hamirani K, Klapholz M, Saric M. Sudden cardiac death in a
young man with takotsubo cardiomyopathy. International Journal of Angiology. 2006; 15(2):100102.
55. Anis A., Narayan, RL, Kapa, S, Klapholz M, Saric, M. Metastatic signet ring adenocarcinoma:
An unusual cause of cardiac constriction. Mt. Sinai JMedicine. 2006 Oct;73(6):898-901.
PMID:17117320
56. Sanchez-Ross M, Anis, Walia J, Randhawa P, Esrig BC, Banker MC, Eber C, Maldjian P, Klapholz
M, Saric, M. Aortic rupture: comparison of three imaging modalities. Emergency Radiol. 2006
Oct;13(1):31-33. Epub 2006 June 29. PMID: 16807714
57. Liuzzo JP, Shin YT, Lucariello R, Klapholz M, Lang SJ, Braff R, Guan H, Coppola JT, Ambrose
JA. Triple valve repair for rheumatic heart disease. Journal of Cardiac Surgery. 2005 JulAug;20(4):358-363. PMID:1985139
Page 31 of 40
58. Anis A, Brady J, Sedaghat D, Klapholz M, Esrig, BC, Saric M. Papillary fibroelastoma: An
uncommon cause for a transient ischemic attack. American Journal of Geriatric Cardiology. 2005
14(5):269-270.
59. WF Peacock IV, R Holland, R Gyarmathy, L Dunbar, Klapholz M, DP Horton, G DeLissovoy,
and CL Emerman. Observation Unit Treatment of Heart Failure with Nesiritide: Results from the
Proaction Trial. Journal of Emergency Med. 2005; 29(3):243-252.
60. Kurian DC, Wagner IJ, Klapholz M. Nesiritide in pulmonary hypertension. Chest. 2004 Jul;
126(1):302-305. PMID:15249476
61. Gheorghiade, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza
RL, McGrew FA, Klapholz, M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a
Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. JAMA.
2004;Apr 28;291(16):1963-1971.
62. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, Kalman J, Phillips RA,
Steingart R, Brown EJ Jr, Berkowtiz R, Moskowitz R, Soni A, Mancini D, Bijou R, Sehhat K,
Varshneya N, Kukin M, Katz SD, Sleeper LA, LeJemtel TH; New York Heart Failure Consortium.
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of
the New York Heart Failure Registry. Journal of American Coll of Cardiology. 2004 Apr
21;43(8):1432-1438.
63. Klapholz M. Heart Failure in the elderly. Heart Disease. 2003 Jul-Aug;5(4):241-243.
PMID:12877757
64. Klapholz M, MD. Editorial: Systolic and Diastolic Heart Failure. Heart Disease. 2003;5;3.
65. Kostis JB, Klapholz M, Delaney C, Vesterqvist O, Cohen M, Manning JA Jr, Jemal M, Kollia GD,
Liao WC. Pharmacodynamics and Pharmacokinetics of Omapatrilat in Heart Failure. Journal of
Clinical Pharmacology 2001; 41(12):1280-1290.
66. Klapholz M, Thomas I, Eng C, Iteld BJ, Ponce GA, Niederman AL, Bilsker M, Heywood JT,
Synhorst D. Effects of Omapatrilat on Hemodynamics and Safety in Patients with Heart Failure.
American Journal of Cardiology. 2001; 15;88(6):657-661.
67. IMPRESS study group: Comparison of Vasopeptidase Inhibitor, Omapatrilat, and Lisinopril on
Exercise Tolerance and Morbidity In Patients with Heart Failure: IMPRESS randomized trial. The
LANCET. August 2000; Vol. 356, No. 9230 Pages 615-620. Klapholz M. Study Group Member.
68. U.S. Carvedilol Heart Failure Study Group: The Effect of Carvedilol on Morbidity and Mortality in
Patients with Chronic Heart Failure. The New England Journal of Medicine. Vol 334:21 1349-1355,
May 23, 1996. Klapholz M. Study Group Member.
69. Ismail A, Frishman WH, Klapholz M. Smoking, Nicotine, Nicotine Replacement, and
Cardiovascular Disease. Am J Ther. 1996 May;3(5):348-357. PMID:1186227
70. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML,
Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE,
LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind placebo controlled study of the
effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial.
Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;
94(11):2793-2799.
71. Cavusoglu E, Frishman WH, Klapholz M. Vesnarinone: a new inotropic agent for treating
congestive heart failure. Journal of Cardiac Failure 1995; 1(3):249-257.
Page 32 of 40
72. Katz SD, Klapholz M, Jondeau G. Galvao M, Levato P, Solomon S, Le Jemtel TH. EndotheliumDependent Vasodilatation is Improved by Physical Training in Normal Subjects. Proceeding of the
5th World Congress on Cardiac Rehabilitation. 1993 Intercept Ltd., Andover, UK 4:229-237.
73. Jondeau G, Klapholz M, Katz SD, Maher M, Galvao M, Levato P, Le Jemtel TH. Control of
Arteriolar Resistance in Heart Failure: Partial Attenuation of Specific Phosphodiesterase InhibitorMedicated Vasodilation by Digitalis Glycosides. Circulation 1992; 85(1):54-60.
B.
Books, Monographs and Chapters
1.
LeJemtel TH, Klapholz M, Frishman WH. Inotropic Agents, In W. Frishman, and D. Sica (Eds),
Cardiovascular Pharmacotherapeutics (3rd Ed). New York, McGraw Hill; (2011).
2.
Klapholz M, Buttrick P. (2003), Sex Specific Differences in Myocardial Function and
Cardiomyopathy, In P. Douglas (ED) Cardiovascular Health and Disease in Women. (Pages 105117), Philadelphia, W.B. Saunders Company.
3.
Mayerson Adam B, Klapholz Marc, and Frishman William H. (2003), Vasopressin and
Vasopressin Receptor Antagonists in Cardiovascular Disease, In W. Frohman, E. Sonnenblock
and D. Sica (Eds), Cardiovascular Pharmacotherapeutics (2nd Ed, Pages 601-617), New York,
McGraw Hill.
C.
Patents Held
None
D.
Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional
Communications
1.
Patel A, Waller AH, Rusovici A, Dhruvakumar S, Maher J, Gerula C, Haider B, Klapholz M, Kaluski
E. Routine stress testing post percutaneous coronary intervention. Minerva Cardioangiol. 2011
Aug;59(4):321-330.
2.
Kaluski E, Waller A, Patel, A, Gerula G, Maher J, Haider B, Klapholz M. Clinical applicability of
atherosclerotic lesion characterization. Minerva Cardioangiol. 2011 June;59(3)255-270.
3.
Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. Osteopontin in Cardiovascular Disease: a
potential therapeutic target. Cardiology Review. 2010 May-June;18(3):125-31.
4.
Kaluski E, Tsai S, Milo-Cotter, Klapholz M. “Buddy in jail” or “buried wire” method: a critical
review. Catheter Cardiovasc Interv. 2010;75(5):814.
5.
Rezaizadeh H, Sanchez-Ross, Kaluski E, Klapholz M, Haider B, Gerula C. Acute Eosinophilic
Myocarditis: Diagnosis and Treatment. Acute Cardiology Care. 2010;12(1):31-36.
6.
Marc Klapholz. β-Blocker Use for the Stages of Heart Failure. Mayo Clinic. August
2009;84(8):718-729.
7.
Edo Kaluski, Steve Tsai, Marc Klapholz. Coronary stenting with MGuard: from conception to
human trials. Cardiovasc Revasc Med. 2008 Apr-Jun(9)(2):88-94.
8.
Kaluski E, Klapholz M. Nitric Oxide Synthase Inhibitors in Cardiogenic Shock-Present and Future.
Future Cardiology. 2008; Vol. 4, No. 2, 183-189.
9.
Kaluski E, Klapholz M. Nitric Oxide Synthase Inhibitors in Post-Myocardial Infarction Cardiogenic
Shock - An Unfulfilled Promise? Acute Cardiac Care. 2007; 9:164-165.
Page 33 of 40
10. Kaluski E, Haider B, Milo Cotter O, Klapholz M. Glycoprotein IIb/IIIa Inhibitors-Questioning the
indications and treatment algorithms. Cardiovas Revas Med. 2007; 8:281-288.
11. Stoupakis G, Klapholz M. Natriuretic peptides: biochemistry, physiology and therapeutic role in
heart failure. Heart Disease. 2003 May-Jun; 5(3):215-223. PMID:12783635
12. Cavosogh V, Frishman WH, Klapholz M. Vesnarinone: A New Inotropic Agent for Treating
Congestive Heart Failure. Journal of Cardiac Failure. Vol 1:3, 249-257, July 1995.
13. Ismail A, Frishman WH, Klapholz M. Smoking, Nicotine, Nicotine Replacement and Cardiovascular
Disease. American Journal of Therapeutics 1996; 3(5):348-357.
14. Klapholz M, LeJemtel TH. Update on the Pathophysiology of Congestive Heart Failure. Resident
Staff Physician. 1990; 21-26.
15. Le Jemtel TH, Katz SD, Forman R, Klapholz M. Clinical Perspectives on Positive Inotropic
Therapy for Chronic Congestive Heart Failure. Cardiovascular Drug Review. 1989; 7(4):301-309.
E.
Abstracts
1.
Alhaj E, Ahmad US, Niazi OT, Zakhary D, Akhtar M, Zabolotsky A, Oriscello R, Voudouris A,
Kaluski E, Klapholz M. Atypical stress-induced cardiomyopathy: a case series. Published in Acta
Cardiol. April;68(2):222-225.
2.
Rudzinski W, Waller A, Rusovici A, Klapholz M, Kaluski E. Comparison of efficacy and safety
of intracoronary nitroprusside and intervenous adenosine for fractional flow reserve. ACC
Moderated Poster Session, Chicago, IL. March 25, 2012. Published in Journal American Coll of
Cardiol. March 27, 2012; 59(13):E412.
3.
Nasur A, Cruz C, Dehnee A, Rudsinski W, Benz M, Klapholz M, Kaluski E. TIMI frame count:
Is it an adequate measure for embolization during stenting in primary PCI? Cardiovascular
Research Technologies 2012 meeting. Abstract # Poster presentation, Washington, DC. February
7, 2012.
4.
Dehnee A, Rudzinski W, Waller A, Sanchez S, Benz M, Klapholz M, Kaluski E. Intracoronary
Nitroprusside results in faster, uniform and uneventful maximal coronary vasodilation during
fractional flow reserve measurements. Voted among 10 best abstracts and selected for oral
presentation. Cardiovascular Research Technologies 2012 meeting. Abstract #307. Washington,
DC. February 7, 2012.
5.
Rudzinski W, Sanchez S, Cruz C, Benz M, Randhawa P, Riley J, Klapholz M, Kaluski E.
Intracoronary Sodium Nitroprusside may be the preferred vasodilator for fractional flow reserve
(FFR) study. Presented in Society of Cardiovascular Angiography and Interventions 34 th Annual
Scientific Meeting 2011. Abstract # C022. Baltimore, MD. May 5, 2011. Published in Catheter
Cardiovasc Interv. 2011;May 1(77-6) S-67.
6.
Sanchez S, Benz M, Randhawa P, Cruz C, Rudzinski w, Riley R, Klapholz M, Gerula C, Kaluski
E. Intracoronary Nitroprusside is the preferred vasodilator for fractional flow reserve. Presented
in Cardiovascular Research Technologies 2011 meeting. Abstract #122. Washington, DC.
February 27, 2011.
7.
Reilly J, Matute D, Benz M, Randhawa P, Cruz C, Drakes C, Gerula C, Klapholz M, Kaluski E.
Change of Glycoprotein IIb/IIIa Inhibitors Strategies in Percutaneous Coronary Interventions and
the Rate of Ischemic and Bleeding Complications. Presented in Cardiovascular Research
Technologies 2011 meeting. Abstract #121. Washington, DC. February 27, 2011.
Page 34 of 40
8.
Kasper M, Kaluski E, Sanchez Ross M, Tsyvine D, Maher J, Patel B, Dougan W, Langley D,
Klapholz M. Pre Hospital EKG Transmission and Direct Cath Lab Admission Shortens
Recognition-to-Reperfusion Time in Primary Percutaneous Coronary Intervention and Improves
Outcomes. Presented at TCT 2010, September 22, 2010. Published in American College of
Cardiology. 2010 TCT Supplement, #428.
9.
Tsyvine D, Sanchez Ross M, Kasper M, Kaluski E, Maher J, Gerula C, Dougan W, Langley D,
Klapholz M. New therapeutic algorithms may eliminate gender bias in the treatment of ST
elevation myocardial infarction. Presented at TCT 2010, September 22, 2010. Published in
Journal of American College of Cardiology. 2010 TCT Supplement, #467.
10. Sanchez-Ross Monica, Oghlakian Gerard, Maher James, Kasper Mike, Dhruva Vivek, Kaluski
Edo, Klapholz Marc. Ripple Effects of a Novel D2B Pathway. Published in Journal of
American College of Cardiology. 2010;55:A109.E1013.
11. Kaluski E, Benz M, Solanki P, Alfano D, Randhawa P, Klapholz M. Right coronary artery
anatomical variants: Where and how? Poster #329 CRT Meeting. Washington DC. Presented
February 21, 2010.
12. Kaluski E, Maher J, Gerula C, Sedaghat D, Shehadeh A, Klapholz M. Wireless technology in
acute ST elevation myocardial infarction. Presented in Euro-PCR on May 22, 2009. Published in
Eurointervention 2009(5); Suppl. E-101.
13. Sanchez-Ross Monica, Oghlakian Gerard, Maher James, Sedaghat David, Dhruva Vivek, Kaluski
Edo, Klapholz Marc. Wireless Technology Improve Outcomes and Eliminates Gender Bias in
Acute Myocardial Infarction. Circulation. 2009;120:S961.
14. Kaluski E, Gerula C, Maher, J, Klapholz M. Burification balloon and stent platform to simplify
and optimize bifurcation interventions. Presented in Euro-PCR on May 20, 2009. Published in
Eurointervention. 2009(5); Suppl. E-33.
15. Kaluski Edo, Klapholz Marc, Gerula Christine. “Bifurcation Balloon and Stent Platform: Simple
Comprehensive Anatomically Correct”. Presented at the CRT Meeting, Washington, DC. March
4, 2009. Published in Cardiovasc Revasc Med. 2009:10:268.
16. Kaluski Edo, Gerula Christine, Maher James, Klapholz Marc. “I Wish I Knew That!” – Beyond
Door to Intervention Time or “Everything You Wanted to Know About Your STEMI Patient PrePCI and Never Dared to Ask”. Presented at the CRT Meeting, Washington, DC. March 2009.
Published in Cardiovasc Revasc Med. 2009;10:265.
17. Sedaghat D, Zakir RM, Choe J, Klapholz M, Saric M. Cardiac amyloidosis in a patient with
multiple myeloma: A case report and review of literature. Journal of Clinical Ultrasound. January
28, 2009.
18. Maher James, Kaluski Edo, Gerula Christine, Klapholz Marc. Automated Wireless Network
Enhances STEMI Patient Triage, Reduces Door to Intervention Time, and Improves Patient
Outcome. Presented at the CRT Meeting, Washington, DC. March 4, 2009. Published in
Cardiovasc Revasc Med. 2009; 10:268.
19. Kaluski E, Klapholz M. Bifurcation balloon and stent platform. A new innovation to simplify
and optimize bifurcations interventions. International Innovations in Cardiology (ICI) meeting
Tel-Aviv, December 7, 2008.
20. Kaluski E, Maher JM, Klapholz M. ST Segment analysis using wireless technology in acute
myocardial infarction. International Innovations in Cardiology (ICI) Meeting Tel-Aviv, December
7, 2008.
Page 35 of 40
21. Maher JM, Dhruva VN, Zakir R, Kaluski E, Klapholz M. ST-Segment analysis using wireless
technology in acute myocardial infarction (STAT-MI) trial: follow-up report. Presented at the
2008 European Society of Cardiology Meeting, Munich. Published in the European Heart
Journal. 2008; 29 (Abstract Supplement), 674P.
22. Maher JM, Dhruva VN, Solanki P, Zakir R, Kaluski E, Klapholz M. ST-Segment Analysis Using
Wireless Technology in Acute Myocardial Infarction (STAT-MI) Trial: Early versus Late
Experience. Accepted for poster presentation, AHA 2008 November 9, 2008. Abstract poster
session. Circulation. 2008;118:S-578(549).
23. Kaluski, Alfano D, Randhawa P, Palmaro J, Jones P, Romano K., Dolny-Korasick D, Klapholz M.
Length of Hospital Stay after Percutaneous Coronary Interventions. Accepted for CRT Meeting,
Washington, DC. February 12, 2008.
24. M. Klapholz, WT JK Ghali, P. Ponikowski, B. Knusel, SM Wasserman, Y. Sun, DJ Van Veldhuisen.
Pooled safety analysis of darbeopoetin alfa in the treatment of symptomatic heart failure. Accepted
ESC Congress 2008.
25. Tsai Steve, Sedaghat David, Peter Pallavi, Patel Rajiv, Rafiq Adnan, Dever Lisa, Saric Muhamed,
Klapholz Marc, Oriscello Ralph. Myocardial Infarction as a result of Babesiosis. UMDNJ, 5th
Annual Department of Medicine Research Day 2007.
26. Tsai Steve, Dhurva Vivek, Peter Pallavi, Mizyed Ahmed, Kats Yuliya, Hamirani Kamran, Saric
Muhamed, Maldjian Pierre, Klapholz Marc. Anomalous Left Coronary Artery from the Pulmonary
Artery. UMDNJ, 5th Annual Department of Medicine Research Day 2007.
27. Tsai S, Kaluski E, Klapholz M. Long term IABP for cardiogenic shock due to acute mitral
regurgitation super imposed on dilated cardiomyopathy. Oral presentation at TCT, October 2007,
Washington, DC.
28. Zakir Ramzan M, Patel Rajiv, Abro Zulqarnain, Anis Ather, Saric Muhamed, Klapholz Marc.
Hypertension in African Americans with Heart Failure: Progression from Hypertrophy to
Dilatation; Perhaps Not. Journal of Cardiac Failure 2007;13(6):S100.
29. Dhruva VN, Abdelhadi S, Anis A, Gluckman W, Shahidi H, Ahuja S, Atkin S, Klapholz M. STSegment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) Trial.
Accepted for presentation, Society of Coronary Angiography and Intervention. May 2007.
Award for Best Abstract.
30. Dhruva VN, Abdelhadi S, Anis A, Gluckman W, Shahidi H, Ahuja S, Atkin S, Klapholz M. STSegment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) Trial.
Journal of American College of Cardiology. 2007;50(6):509-513.
31. Zakir RM, Patel RJ, Ahuja S, Saric M, Klapholz M. Increases in left ventricular mass is more
pronounced in low ejection fraction versus normal ejection heart failure. Journal of Cardiac
Failure. 2005;11(6): S395.
32. Anis A, Rafiq A, Abdelhadi S, Maldjian PD, Manela D, Zakir R, Saric M, Klapholz M.
Correlation between chest radiograph and serum brain natriuretic peptide levels in patients
presenting with dyspnea. Chest. 2006;130(4):195S-196S.
33. Anis A, Saric M, Haider B, Cohen ZI, Ather A, Klapholz M. Lupus myocarditis treated with
intravenous immunoglobulin under hemodynamic monitoring. Oral Presentation. 72nd Annual
International Scientific Assembly of the American College of Chest Physicians, October 23, 2006
in Salt Lake City, UT. Chest. 2006;130(4):292S.
Page 36 of 40
34. Anis A, Patel B, Williamsom M, Dhruva V.N, Ahuja S, Levine J, Saric M, Klapholz M.
Incidence of obstructive coronary artery disease in intensive care unit patients admitted with
cardiac and non cardiac diagnoses with modest troponin elevation. 72nd Annual International
Scientific Assembly of the American College of Chest Physicians, October 25, 2006 in Salt Lake
City, UT. Chest. 2006; 130(4): 198S.
35. Anis A, Rafig A, Abdelhadi,S, Maldjian PD, Manela D, Zakir R, Saric M, Klapholz M.
Correlation between chest radiograph and serum brain natriuretic peptide levels in patients
presenting with dyspnea. Chest. 2006; 06:130(4):195S-196S.
36. Anis A, Saric M, Cohen ZI, Haider B, Klapholz M. Lupus myocarditis treated with intravenous
immunoglobin under hemodynamic monitoring. American College of Chest Physicians. Chest.
2006; 130(4).
37. Manela David, Levine Jason, Klapholz Marc. The Ratio of Pulse Pressure/Stroke Volume Index,
a Marker of Total Arterial Compliance: Its Correlation with Abnormal Left Ventricular
Geometry. Circulation. 2006, Vol. 114, No. 18:3159.
38. Manela David, Levine Jason C, Maher James, Klapholz Marc. The Significance of a Reverse
Pattern In Pulse Pressure Amplification in Predicting Coronary Artery Disease and Abnormal Left
Ventricular Remodeling in Patients with Hypertension. Circulation. 2006, Vol. 114, No.
18:2596.
39. Zakir RM, Patel, RJ, Ahuja S, Saric M, Klapholz M. Increases in left ventricular mass is more
pronounced in low ejection fraction versus normal ejection heart failure. Abstract presented at
Heart Failure Society of America, 2006. Journal of Cardiac Failure. 2006, Vol. 12, Issue 6
(Supplement), S28.
40. Manela David Y, Levine Jason C, Anis Ather, Klapholz Marc. Use of the 12 Lead EKG in
Distinguishing Concentric LV Remodeling from Normal LV Geometry. Heart Failure Society of
America 2006.
41. Manela David Y, Levine Jason C, Anis Ather, Klapholz Marc. The Relationship between the
Pulse Pressure/Stroke Volume and Index and Abnormal Left Ventricular Geometry. Heart Failure
Society of America, 2006.
42. Manela David Y, Levine Jason C, Anis Ather, Klapholz Marc. Reverse Pulse Pressure
Amplification: Its Role in Predicting Coronary Artery Disease and Abnormal LV Remodeling.
Heart Failure Society of America, 2006.
43. Van Veldhuisen DJ, Klapholz M, Anand I, Wasserman SM, Knusel B, Rosser D, Baker N,
Abraham WT, Sun Y. The effect of increased hemoglobin concentration on clinical outcomes in
patients with symptomatic heart failure and anemia: a pooled analysis of two randomized, doubleblind, placebo-controlled trials. European Society of Cardiology, 2006.
44. Abraham WT, Klapholz M, Anand I, Knusel B, Rosser D, Baker N, Sun Y, Van Veldhuisen DJ.
The effect of darbeopoetin alfa treatment on clinical outcomes in anemic patients with
sympotomatic heart failure: a preplanned pooled analysis of two randomized, double-blind
placebo-controlled trials. European Society of Cardiology, 2006.
45. Eichhorn Eric, Metra Marco, Abraham William, Amuchasetegui Macros, Binkley Philip, Bohm
Michael, Deedwania Prakash, Demarco Teresa, Elkayam Uri, Ford Ian, Ghali Jalal, Guzman Luis,
Klapholz Marc, Kuschnir Emilio, Liu Peter, Perna Eduardo, Perrone Sergio, Mareev Vyacheslay,
Yao Louis, Soller-Soler Jordi, Komajda Michael, Poole-Wilson Philip, Tendera Michae, Dargie
Henry, Swedberg Karl, Lowes Brian, and Bristow Michael on behalf of ESSENTIAL Study
Group.
Page 37 of 40
ESSENTIAL – The Studies of Oral Enoximone Therapy in Advanced Heart Failure. Myogen,
Inc., Westminister, CO, USA. Presented at Heart Failure Society of America. September 2005.
46. Reinherz L., Malkani Anita, Coppola John, Elmquist Thomas, Braff Robert, Mannino Salvatore,
Tamburrino Frank, Sehhat Khashayar, Voudouris Apostolos, Giordano Robin, Burcham Joyce,
Kudithipudi Vijayasree, LeJemtel Theirry, Klapholz Marc. Left ventricular End Systolic Volume
Predicts serum Levels of Brian Natriuretic Peptide in a Multivariate Model of Hemodynamic,
Volumetric and Wall Stress Parameters. Presented at Heart Failure Society of America.
September 2003.
47. Klapholz M, Varshneya N, Hernandez E, Voleti R, Bhargava S, Kudithipudi V, Tai Z, Gupta R,
Ratnasiri G, Sehhat K, Hanah M, Ambrose J, Burcham J, LeJemtel TH. Long Term ReHospitalization Rates and Mortality of Patients Hospitalized for Heart Failure with a Normal
Ejection Fraction. Supplement of Journal of American College of Cardiology. 2003; Vol. 41 No.
6:184A.
48. Klapholz Marc, Palla Venu, Moskowitz Robert, Berkowitz Robert, Meisner Jay S, et al. Racial
Differences Among Patients Hospitalized for Heart Failure with Normal Systolic Function:
Results of the New York Heart Failure Consortium Registry on Diastolic Dysfunction. Oral
presentation, Scientific Session American Heart Association Supplement to Circulation. 2001;
Vol. 104, No. 18:3252.
49. Klapholz Marc, Mitchell Judith, Meisner Jay S, Kalman Jill, Steingart Richard, et al. Clinical
Characteristics and Co-Morbid Conditions of Patients Hospitalized for Heart Failure with Normal
Systolic Function: Results of the New York Heart Failure Consortium Registry on Diastolic
Dysfunction. Oral presentation, Scientific Session American Heart Association Supplement to
Circulation. 2001; Vol. 104, No. 18:3253.
50. Mitchell Judith, Klapholz Marc, Meisner Jay S, Kalman Jill, Steingart Richard, et al. Therapeutic
Management of Patients Hospitalized for Heart Failure with Normal Systolic Function: Results of
the New York Heart Failure Consortium Registry on Diastolic Dysfunction. Oral presentation,
Scientific Session American Heart Association Supplement to Circulation. 2001; Vol. 104, No.
18:3210.
51. Klapholz Marc, Palla Venu, Moskowitz Robert, Berkowitz Robert, Meisner Jay S, Kalman Jill,
Mitchell Judith, Soni Anita, Kukin Marrick, Bijou Rachael, Lowe April, Katz Stuart, Mancini
Donna, LeJemtel Thierry. Racial Differences Among Patients Hospitalized for Heart Failure with
Normal Systolic Function: Results of the New York Heart Failure Consortium Registry on
Diastolic Dysfunction. Oral presentation at Heart Failure Society of America Meetings. Journal
of Cardiac Failure. 2001; Supplement 2, Vol. 7, No. 3:260.
52. Klapholz Marc, Mitchell Judith, Meisner Jay S, Kalman Jill, Steingart Richard, Khashayar
Sehhat, Varshneya Nikita, Maurer Matthew, Phillips Robert A., Sleeper Lynn, Brown Edward,
Katz Stuart, LeJemtel Thierry. Clinical Characteristics and Co-Morbid Conditions of Patients
Hospitalized with Heart Failure and Normal Systolic Function Results of the New York Heart
Failure Consortium Registry on Diastolic Dysfunction. Oral presentation, Heart Failure Society of
America Meetings. Journal of Cardiac Failure. 2001; Supplement 2, Vol. 7, No. 3:250.
53. Tighe Foss, Klapholz Marc, Nisbet-Brown Julia, Katz Stuart, Nash Patti, Maurer Matthew,
Meisner Jay, Kukin Marrick, Mitchell Judith, Baran Dave, Bijou Rachel, Kalman Jill, Steingart
Richard, Phillips Robert and LeJemtel Thierry. An ‘Intelligent’ On-line Multicenter Database
Created for The Greater New York Heart Failure Consortium Registry on Heart Failure with
Preserved Left Ventricular Systolic Function. Presented American College of Cardiology,
Scientific Sessions. March 2001: Database Applications in Cardiology: Info@ACC.
54. Klapholz Marc, M.D., Brown, Jr. Edward J, M.D., Niederman Alan L, M.D, and Heywood J.
Thomas, M.D, for the Omapatrilat Heart Failure Investigators: Safety and efficacy of the
Page 38 of 40
vasopeptidase inhibitor in patients with both heart failure and systolic hypertension. Journal of
Cardiac Failure, Volume 6, Number 3 Supplement 2. Presented at Heart Failure Society of
American Meeting. September 2000.
55. Abraham Prof. William, Koren Dr. Michael, Bichet Dr. Daniel G., Verbalis Prof. Joseph G,
Klapholz Dr. Marc, Selaru Ms. Paulina, Bakker-Arkema Ms. Rebecca, Rummel Dr. Sue A.
Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan
(YM087), a new combined vasopressin V1A/V2 receptor antagonist. European Heart Journal,
Volume 21 Abstr. Suppl. August/September 2000.
56. Kostis John, Klapholz Marc, Delaney Carol, Liao Wei-chi. Plasma Atrial Natriuretic Peptide,
Cyclic Guanosine Monophosphate, and Endothelin Response to Omapatrilat in Heart Failure.
Supplement to Journal of the American College of Cardiology, February 2000, Vol. 35, Issue 2,
Suppl. A, Page 206. Presented at the American College of Cardiology - Scientific Sessions,
March 2000.
57. Klapholz M, Thomas Ignatius, Eng Calvin, Iteld Bruce et al. Omapatrilat, a Novel Cardiovascular
Agent, Improves Hemodynamics in Patients with Heart Failure. Circulation, Suppl 1; Vol 98, No 17,
I-105.
58. Klapholz M, Thomas Ignatius, Eng Calvin, Iteld Bruce et al. Omapatrilat, an inhibitor of Neutral
Endopeptidase (NEP) and Angiotensin Converting Enzyme (ACE), Improves Hemodynamics in
Patients with Heart Failure. Presentation, Heart Failure Society Meetings September, 1998. Journal
of Cardiac Failure, Suppl 1; Vol 4, No 3:153.
59. Packer M, Colucci WS, Sackner-Bernstein J, Liang CS, Goldscher DA, Freeman I, Kukin ML,
Kinhal V, Udelson JE, Klapholz, M, for the Precise Study Group: Prospective Randomized
Evaluation of Carvedilol on Symptoms and Exercise Tolerance in Chronic Heart Failure: (Results of
the Precise Trial). American Heart Association, 68th Scientific Sessions, November, 1995.
92(9):2284.
60. Ehlert F, Zelenkofske SL, Prasher S, Klapholz M, Steinberg JS. Asymptomatic Nonsustained
Ventricular Tachycardia Does Not Predict Future Events in Patients with Idiopathic Cardiomyopathy.
NASPE 15th Annual Scientific Sessions. January, 1994.
61. Yuen JL, Bijou R, Katz S, Klapholz M, LeJemtel TH. Intense Limb Training Improves Vascular
Endothelium Function In Normal Subjects And In Patients With Congestive Heart Failure. Young
Investigators’ Awards, 1993.
62. Katz SD, Klapholz M, Jondeau G, Solomon S, Galvao M, Levato P, LeJemtel TH. Regional
Vascular Responses to Endothelium-Dependent and Independent Vasodilatory Stimuli Before and
After Physical Training in Normal Subjects. Circulation. 1991; 84:4; II-540.
63. Lazar Eliot J, Klapholz M, Lefkowitz D, Lazar JM, Schwartz M, Ann Mitzner, Paul Simonoff, Mark
Heiman, William H. Frishman. Right Precordial ST Deviation predicts Pulmonary Hypertension.
Chest . 1990; Vol. 98:92.
64. Katz SD, Jondeau G, Biasucci L, Klapholz M, Lee K, Marantz P, Nanna M. Left Ventricular
Thrombus and Incidence of Stroke in Patients with Congestive Heart Failure. A Prospective Study.
Circulation. 1990; 82:4 III-470.
65. Jondedau G, Klapholz M, Katz SD, Galvao M, Levato P, LeJemtel, TH. Digoxin Attenuates the
Direct Vasodilating Action of Specific Phosphodiesterase Inhibitors in Congestive Heart Failure.
Circulation. 1990; 82:4 III-316.
Page 39 of 40
66. Klapholz M, Lazar EJ, Lefkowitz D, Fein B, Shipley N, Ama D, Frishman W. Failure of Emergency
Transvenous Pacemaker Insertion to Affect Prognosis in Cardiopulmonary Arrest. Chest . 1989;
96:289S.
F.
Reports
PRESENTATIONS:
A. Scientific
B. Professional
None
Cardiovascular Symposia
Advances in Cardiovascular Disease Management for the Primary Care Physician
Chair - Marc Klapholz, MD
CME Sponsor: University of Medicine & Dentistry of New Jersey
Advances in Cardiovascular Disease Management for the Primary Care Physician
Chair - Marc Klapholz, MD
CME Sponsor: University of Medicine & Dentistry of New Jersey
Page 40 of 40
October 2006
October 2005